

1 **cAMP–EPAC–PKC $\epsilon$ –RIM1 $\alpha$  signaling regulates presynaptic**  
2 **long-term potentiation and motor learning**

3

4 Xin-Tai Wang<sup>1,2†</sup>, Lin Zhou<sup>1†</sup>, Fang-Xiao Xu<sup>1</sup>, De-Juan Wang<sup>1</sup>, Xin-Yu Cai<sup>1</sup>, Yin Wang<sup>3</sup>,  
5 Sheng-Jian Ji,<sup>4</sup> Martijn Schonewille<sup>5</sup>, J. Julius Zhu<sup>6\*</sup>, Chris I. De Zeeuw<sup>5,7,\*</sup>, Ying Shen<sup>1,\*</sup>

6

7 <sup>1</sup>Department of Physiology and Department of Psychiatry, Sir Run Run Shaw Hospital, Zhejiang  
8 University School of Medicine, Hangzhou 310058, China; <sup>2</sup>Institute of Life Sciences, College of  
9 Life and Environmental Sciences, Hangzhou Normal University, Hangzhou 311121, China; <sup>3</sup>Key  
10 Laboratory of Cranial Cerebral Diseases, Department of Neurobiology of Basic Medical College,  
11 Ningxia Medical University, Yinchuan 750004, China; <sup>4</sup>Department of Biology, Southern  
12 University of Science and Technology, Shenzhen 518055, China; <sup>5</sup>Department of Neuroscience,  
13 Erasmus MC, 3000 DR Rotterdam, The Netherlands; <sup>6</sup>Department of Pharmacology, University  
14 of Virginia, Charlottesville, VA 22904, U.S.A.; <sup>7</sup>Netherlands Institute for Neuroscience, Royal  
15 Academy of Sciences, 1105 BA Amsterdam, The Netherlands.

16

17 **\*For correspondence:** yshen@zju.edu.cn or c.dezeeuw@erasmusmc.nl or jjz4n@virginia.edu.

18 <sup>†</sup>These authors contributed equally to this work.

19

20 **Competing interests:** The authors declare that no competing interests exist.

21

22 **Abstract**

23 The cerebellum is involved in learning of fine motor skills, yet whether presynaptic plasticity  
24 contributes to such learning remains elusive. Here we report that the EPAC-PKC $\epsilon$  module has a  
25 critical role in a presynaptic form of long-term potentiation in the cerebellum and motor behavior.  
26 Presynaptic cAMP-EPAC-PKC $\epsilon$  signaling cascade induces a previously unidentified threonine  
27 phosphorylation of RIM1 $\alpha$ , and thereby initiates the assembly of the Rab3A-RIM1 $\alpha$ -Munc13-1  
28 tripartite complex that facilitates docking and release of synaptic vesicles. Granule cell-specific  
29 blocking of EPAC-PKC $\epsilon$  signaling abolishes presynaptic long-term potentiation at the parallel  
30 fiber to Purkinje cell synapses and impairs basic performance and learning of cerebellar motor  
31 behavior. These results unveil a functional relevance of presynaptic plasticity that is regulated  
32 through a novel signaling cascade, thereby enriching the spectrum of cerebellar learning  
33 mechanisms.

## 34 **Introduction**

35 The cerebellum has historically been viewed as a motor coordination center (*Ito, 2005*). Recent  
36 evidence implicates that the cerebellum is also involved in a variety of learning-dependent  
37 high-level behaviors, including motor precision (*Wagner and Luo, 2020; De Zeeuw, 2021*) as well  
38 as cognitive and emotional functions (*Schmahmann et al., 2019*). The unique capability of the  
39 cerebellum to govern fine-tuned motor and cognitive skills at a high temporal resolution critically  
40 depends on delicate coordination of multiple forms of plasticity (*De Zeeuw, 2021*). Indeed, recent  
41 studies indicate that, in addition to the renowned postsynaptic long-term depression (LTD) (*Ito,*  
42 *2005*) and long-term potentiation (LTP) (*Schonewille et al., 2010*), other forms of synaptic or  
43 non-synaptic plasticity may also contribute to cerebellar motor learning (*Raymond and Medina,*  
44 *2018; De Zeeuw, 2021*). However, the molecular underpinnings of presynaptic plasticity in the  
45 cerebellar cortex are merely starting to be explored (*Wang et al., 2021a*), and more importantly,  
46 whether presynaptic plasticity plays a role in cerebellar motor learning remains to be elucidated (*Le*  
47 *Guen and De Zeeuw, 2010; De Zeeuw, 2021*).

48 In this study, we identified a new presynaptic signaling module that comprises EPAC  
49 (exchange protein directly activated by cyclic adenosine monophosphate, cAMP) and PKC $\epsilon$   
50 (epsilon isozyme of protein kinase C), which turns out to control threonine phosphorylation of  
51 RIM1 $\alpha$ , initiate assembly of a Rab3A-RIM1 $\alpha$ -Munc13-1 tripartite complex, and thereby facilitate  
52 docking and release of synaptic vesicles at parallel fiber (PF) to Purkinje cell (PC) synapses.  
53 Importantly, presynaptic ablation of either EPAC or PKC $\epsilon$  is sufficient to inhibit presynaptic LTP  
54 and impair motor performance and motor learning. These data unveil a new signaling cascade  
55 governing presynaptic LTP and for the first time clarify that presynaptic plasticity is required for

56 cerebellar motor learning.



## 57 **Results**

### 58 **EPAC induces PKC $\epsilon$ -dependent threonine phosphorylation of RIM1 $\alpha$**

59 In order to study the function of EPACs at synapses, a series of centrifugations were employed to  
60 prepare cerebellar synaptosomes containing a number of synaptic proteins (*Figure 1A*). We found  
61 that most of EPAC1 and EPAC2 overlapped with vesicle glutamate transporter 1 (vGluT1) (*Figure*  
62 *1B*), which is enriched in PF terminals (*Hioki et al., 2013*). Co-immunoprecipitation (co-IP)  
63 performed using synaptosomes showed that both EPAC1 and EPAC2 were precipitated by the  
64 RIM1 antibody (*Figure 1C*), indicating the ability of EPAC to interact with RIM1. To specify the  
65 action of EPAC, RIM1 was extracted from the synaptosomes by anti-RIM1 antibody-based co-IP  
66 (*Figure 1A*). Interestingly, we found that pan-phospho-threonine (p-Thr) antibodies detected only  
67 a weak signal in control synaptosomes, but a strong band in synaptosomes treated with 8-pCPT, a  
68 specific activator of EPAC (*Figure 1D*). In contrast, the level of pan-phospho-serine (p-Ser)  
69 remained unchanged after 8-pCPT treatment (*Figure 1D*). These results were confirmed by  
70 co-transfecting HA-RIM1 $\alpha$  with Flag-EPAC1 or Flag-EPAC2 in HEK cells, where both types of  
71 EPAC as well as RIM1 $\alpha$  were preferentially distributed along the cell membrane (*Figure 1-figure*  
72 *supplement 1A*). Again, HA-RIM1 $\alpha$  was precipitated with the HA antibody to characterize p-Ser  
73 and p-Thr of RIM1 $\alpha$ . Consistent with *in vivo* assay, neither EPAC1 nor EPAC2 altered serine  
74 phosphorylation of RIM1 $\alpha$ , but both increased phosphorylation of threonine (*Figure 1-figure*  
75 *supplement 1B*).

76 Since EPAC is an effector of cAMP, we wondered whether cAMP also causes the  
77 phosphorylation of threonine sites of RIM1, which comprises 27 of such sites (*Figure 1-figure*  
78 *supplement 1C*). Hence, forskolin, an activator of adenylate cyclase, and ESI-09, an inhibitor of

79 EPAC (Gutierrez-Castellanos et al., 2017), were administered to synaptosomes, after which RIM1  
80 p-Thr was measured. RIM1 p-Thr was vastly increased by forskolin alone, but not following  
81 co-application of both forskolin and ESI-09 (*Figure 1E*), indicating that cAMP leads to  
82 EPAC-dependent threonine phosphorylation of RIM1. We continued to examine the consequences  
83 on RIM1 phosphorylation in EPAC1 and EPAC2 double-knockout (*Epac*<sup>dkO</sup>) mice. Using  
84 synaptosomes purified from *Epac*<sup>dkO</sup> mice, we found that RIM1 p-Thr was significantly reduced,  
85 whereas RIM1 p-Ser was unchanged (*Figure 1F*). Meanwhile, knockout of *Epac* did not change  
86 the expression of RIM1 (*Figure 1F*). The difference of RIM1 p-Thr in the *Epac*<sup>dkO</sup> mice was not  
87 accompanied by major structural difference, as EPAC deficiency did not interfere with lobule  
88 thickness or number of PC spines (*Figure 1-figure supplement 2A and B*). Together, these data  
89 strongly indicate that EPAC is necessary and sufficient to induce threonine phosphorylation of  
90 RIM1.

91 EPAC by itself lacks the kinase activity that is required for phosphorylation (*Kawasaki et al.,*  
92 *1998; Cheng et al., 2008*), which raises a question how EPAC mediates the phosphorylation of  
93 RIM1. We hypothesized that EPAC might act on RIM1 through the Rap1-PLC $\epsilon$ -PKC $\epsilon$  module  
94 (*Figure 1G*), which is shown to be activated by EPAC in neuroblastoma cells (*Schmidt et al.,*  
95 *2001*), dorsal root ganglion neurons (*Hucho et al., 2005*), as well as heart cells (*Oestreich et al.,*  
96 *2009*). Our hypothesis was corroborated by several lines of evidence. First, when Flag-EPAC1 and  
97 Flag-EPAC2 were expressed in HEK cells, phosphorylation at PKC $\epsilon$ -S729 was significantly  
98 increased by both EPAC1 or EPAC2 expression, whereas phosphorylation at PKC $\alpha$ -S657 or  
99 PKC $\alpha$ -T638 was not altered (*Figure 1-figure supplement 3A*). Second, PKC $\epsilon$  overlapped with  
100 vGluT1 in cerebellar synaptosomes (*Figure 1H*), suggesting the presence of PKC $\epsilon$  at PF synapses.

101 Western blots showed that phosphorylation at PKC $\epsilon$ -S729, but not at PKC $\alpha$ -S657 or PKC $\alpha$ -T638,  
102 was increased in cerebellar synaptosomes treated with 8-pCPT, whereas control buffer had no  
103 impact (*Figure 1I*). Third, phosphorylation at PKC $\epsilon$ -S729 in the synaptosomes was significantly  
104 reduced by EPAC ablation (*Epac*<sup>dKO</sup> versus WT), whereas phosphorylation at PKC $\alpha$ -S657 or  
105 PKC $\alpha$ -T638 was unchanged (*Figure 1J*). These data indicate that EPAC is able to regulate PKC $\epsilon$   
106 activity. We next investigated whether PKC $\epsilon$  can phosphorylate RIM1 $\alpha$ . HA-RIM1 $\alpha$  and  
107 His-PKC $\epsilon$  were co-transfected into HEK cells and co-IP experiments showed that PKC $\epsilon$  can bind  
108 to RIM1 $\alpha$  (*Figure 1-figure supplement 3B*). In addition, RIM1 $\alpha$  p-Thr was significantly increased  
109 in cells transfected with PKC $\epsilon$  compared to the control (*Figure 1-figure supplement 3C*). To  
110 confirm *in vitro* findings, we generated mice with *Prkce* (the gene coding for PKC $\epsilon$ ) deletion  
111 specifically in cerebellar granule cells (*Prkce*<sup>ckO</sup>) by crossing *Math1-Cre* (*Wang et al., 2021b*)  
112 with *Prkce*<sup>fl/fl</sup> mice (*Figure 1-figure supplement 2C-F*), and *Prkce*<sup>ckO</sup> mice showed normal lobule  
113 thickness and number of spines of PCs (*Figure 1-figure supplement 2G-H*). Subsequently, RIM1  
114 phosphorylation was examined in cerebellar synaptosomes derived from *Prkce*<sup>fl/fl</sup> and *Prkce*<sup>ckO</sup>  
115 mice. Similar to the findings in *Epac*<sup>dKO</sup> mice, RIM1 p-Thr was significantly reduced, whereas  
116 both RIM1 p-Ser and total RIM1 were unchanged in *Prkce*<sup>ckO</sup> mice (*Figure 1K*). These data  
117 indicate that PKC $\epsilon$  is able to regulate RIM1 p-Thr phosphorylation.

118 Finally, several lines of evidence demonstrated the causal relationship between EPAC and  
119 PKC $\epsilon$  on the phosphorylation of RIM1 $\alpha$ . First, we applied 8-pCPT alone or with  $\epsilon$ V1-2 (a  
120 selective PKC $\epsilon$  inhibitor) to WT synaptosomes. The addition of  $\epsilon$ V1-2 to the synaptosomes  
121 strongly attenuated RIM1 p-Thr induced by 8-pCPT (*Figure 1-figure supplement 3D*). In contrast,  
122 RIM1 p-Thr was not affected by co-application of Gö6976, a PKC $\alpha/\beta$  inhibitor (*Figure 1-figure*

123 *supplement 3D*). Second, we administered phorbol 12-myristate 13-acetate (PMA), an activator of  
124 all PKC isoforms, alone or along with  $\epsilon$ V1-2 or Gö6976, so as to inhibit PKC $\epsilon$  or PKC $\alpha/\beta$ ,  
125 respectively.  $\epsilon$ V1-2, but not Gö6976, significantly suppressed RIM1 $\alpha$  p-Thr in the synaptosomes  
126 (*Figure 1–figure supplement 3E*). Third, RIM1 phosphorylation was examined in *Prkce*<sup>ckO</sup>  
127 synaptosomes, which were treated with either control saline or 8-pCPT. In this scenario, neither  
128 p-Thr nor p-Ser of RIM1 was changed (*Figure 1L*). Overall, these data strongly indicate that  
129 EPAC can trigger RIM1 $\alpha$  p-Thr phosphorylation and that this activation requires PKC $\epsilon$ .

130

131 **EPAC-PKC $\epsilon$  module is critical to vesicle docking and presynaptic release through acting on**  
132 **the Rab3A-RIM1 $\alpha$ -Munc13-1 complex**

133 Our finding that the EPAC-PKC $\epsilon$  module regulates RIM1 activity through phosphorylation leads  
134 to an interesting question: does the EPAC-PKC $\epsilon$  module function on synaptic formation and  
135 function through acting on RIM1? which is known to be critical to organization of the presynaptic  
136 active zone and neurotransmitter release (*Schoch et al., 2002; Han et al., 2011; Kaeser et al., 2011;*  
137 *Acuna et al., 2016; Persoon et al., 2019*).

138 To address this question, we first visualized PF-PC synapses using transmission electron  
139 microscopy (EM), in which PF boutons were identified by their presence of synaptic vesicles as  
140 well as their asymmetric synaptic contacts with PC spines (*Figure 2A and B*). No apparent  
141 abnormality was found in the size of the postsynaptic density or the synaptic cleft of PF-PC  
142 synapses in either *Epac*<sup>dkO</sup> ( $n = 4$ ) or *Prkce*<sup>ckO</sup> ( $n = 4$ ) mice, compared to corresponding WT ( $n =$   
143  $4$ ) and *Prkce*<sup>ff</sup> ( $n = 4$ ) mice (*Figure 2A and B*). However, the deletion of *Epac* significantly  
144 decreased the number of the docked vesicle pool (WT:  $2.0 \pm 0.1$  vesicles,  $n = 98$  boutons; *Epac*<sup>dkO</sup>:

145  $1.0 \pm 0.1$  vesicles,  $n = 127$  boutons;  $p < 0.0001$ ) (*Figure 2A*). This difference turned out to be  
146 specific to the active zone, as the total number of vesicles in PF terminals (within 100 nm away  
147 from active zone) was not affected (WT:  $32.8 \pm 2.4$  vesicles,  $n = 98$  boutons;  $Epac^{dKO}$ :  $28.3 \pm 1.5$   
148 vesicles,  $n = 127$  boutons;  $p = 0.15$ ). Similarly, the specific deletion of *Prkce* in granule cells also  
149 decreased the number of vesicles in the docked vesicle pool ( $Prkce^{ff}$ :  $1.6 \pm 0.1$  vesicles,  $n = 60$   
150 boutons;  $Prkce^{cKO}$ :  $0.7 \pm 0.1$  vesicles,  $n = 66$  boutons;  $p < 0.0001$ ) (*Figure 2B*). Meanwhile, the  
151 total number of vesicles in PF terminals was also not affected ( $Prkce^{ff}$ :  $42.1 \pm 2.3$  vesicles,  $n = 57$   
152 boutons;  $Prkce^{cKO}$ :  $39.1 \pm 2.6$  vesicles,  $n = 55$  boutons;  $p = 0.38$ ). These data demonstrate that  
153 both EPAC and PKC $\epsilon$  are required for the docking of presynaptic vesicles.

154 We next examined the effect of the ablation of EPAC or PKC $\epsilon$  on synaptic transmission.  
155 Miniature excitatory synaptic currents (mEPSCs) at PF-PC synapses were recorded in cerebellar  
156 slices from *Math1-Cre;Epac1<sup>ff</sup>;Epac2<sup>ff</sup>* (*Epac1<sup>cKO</sup>;Epac2<sup>cKO</sup>*) and *Prkce<sup>cKO</sup>* mice, the former of  
157 which caused specific deletion of *Epac1* and *Epac2* in granule cells (*Figure 1-figure supplement*  
158 *2I-L*), while *Math1-Cre* and *Prkce<sup>ff</sup>* mice were used as corresponding controls. We found that  
159 mEPSC frequency was reduced in PCs from *Epac1<sup>cKO</sup>;Epac2<sup>cKO</sup>* mice compared to PCs from  
160 *Math1-Cre* mice, whereas mean amplitude did not differ between two genotypes (*Figure 2C*).  
161 Similarly, the frequency but not the amplitude of mEPSCs was significantly lower in *Prkce<sup>cKO</sup>*  
162 mice than corresponding *Prkce<sup>ff</sup>* mice (*Figure 2D*). A decrease in mEPSC frequency may be due  
163 to a reduction in release probability (Pr). To determine if Pr is affected following deletion of  
164 presynaptic *Epac* and *Prkce*, we used a repeated stimulation protocol to estimate the readily  
165 releasable pool (RRP) size as well as Pr. Compared to *Math1-Cre* and *Prkce<sup>ff</sup>* mice, repeated  
166 stimulation (20 Hz) revealed significant reductions in both RRP and Pr in *Epac1<sup>cKO</sup>;Epac2<sup>cKO</sup>*

167 (Figure 2E) and *Prkce*<sup>ckO</sup> mice (Figure 2F). These results indicate that EPAC or PKC $\epsilon$  deficiency  
168 reduces Pr of PF-PC synapses, which is in line with the EM experiment demonstrating a reduced  
169 number of docked vesicles (Figure 2A and B). Overall, these results indicate that the EPAC-PKC $\epsilon$   
170 module is essential to presynaptic transmitter release at PF-PC synapses.

171 We continued to explore how exactly the EPAC-PKC $\epsilon$  module modulates synaptic release.  
172 An essential process during neurotransmitter release is that Rab3A, RIM1 $\alpha$  and Munc13-1 form a  
173 tripartite complex and act in concert to dock synaptic vesicles to a release-competent state (Betz *et*  
174 *al.*, 2001; Wang *et al.*, 2001; Dulubova *et al.*, 2005). Thus, we investigated whether the  
175 EPAC-PKC $\epsilon$  module acts on the Rab3A-RIM1 $\alpha$ -Munc13-1 complex. By measuring the ratios of  
176 IP/input in co-IP assay of synaptosome extracts, we found that both Munc13-1 and Rab3A had  
177 significantly weaker binding ability with RIM1 $\alpha$  in both *Epac*<sup>dkO</sup> (Figure 2G) and *Prkce*<sup>ckO</sup>  
178 (Figure 2H) synaptosomes, as compared to WT and *Prkce*<sup>fl/fl</sup> respectively. In contrast, neither *Epac*  
179 nor *Prkce* ablation changed the expression levels of Rab3A and Munc13 (Figure 2G and H).  
180 These data indicate that the deficiency of either EPAC or PKC $\epsilon$  impairs protein interactions in the  
181 Rab3A-RIM1 $\alpha$ -Munc13-1 complex.

182 In another set of experiments, we studied whether the EPAC-PKC $\epsilon$  module is sufficient to  
183 boost protein interactions in the Rab3A-RIM1 $\alpha$ -Munc13-1 complex. First, we treated WT  
184 synaptosomes with 8-pCPT and  $\epsilon$ V1-2, and measured the amount of Munc13-1 and Rab3A  
185 precipitated with RIM1. The quantification showed a significant increment of precipitated  
186 Munc13-1 and Rab3A when synaptosomes were incubated with 8-pCPT (Figure 2I). Second, we  
187 measured the amounts of precipitated Munc13-1 and Rab3A in WT synaptosomes treated with  
188 FR236924, a selective activator of PKC $\epsilon$ . We found that precipitations of Munc13-1 and Rab3A

189 were both increased (*Figure 2J*). These data indicate that either EPAC or PKC $\epsilon$  is sufficient to  
190 promote the formation of the tripartite complex. In parallel experiments, PKC $\epsilon$  inhibitor  $\epsilon$ V1-2  
191 prevented the increase of precipitated Munc13-1 and Rab3A induced by 8-pCPT (*Figure 2I*),  
192 while FR236924 failed to induce more precipitations of Munc13-1 and Rab3A in *Prkce*<sup>CKO</sup>  
193 synaptosomes (*Figure 2K*). In summary, these data demonstrate that the EPAC-PKC $\epsilon$  module  
194 regulates synaptic organization and transmitter release by regulating the stability of  
195 Rab3A-RIM1 $\alpha$ -Munc13-1 complex.

196

#### 197 **Presynaptic PF-PC LTP depends on EPAC and PKC $\epsilon$**

198 Repetitive stimuli of PF terminals result in an increased Pr of neurotransmitters, leading to the  
199 expression of presynaptic LTP (*Salin et al., 1996; Kimura et al., 1998; van Beugen et al., 2013;*  
200 *Hirano et al., 2016; Kaeser et al., 2008; Yang and Calakos, 2010; Martín et al., 2020*). If the  
201 EPAC-PKC $\epsilon$  module determines transmitter release through regulating the phosphorylation level  
202 of RIM1 $\alpha$ , it is reasonable to hypothesize that this cascade controls presynaptic PF-PC LTP.

203 To test this hypothesis, presynaptic LTP at PF-PC synapses was induced by a tetanus  
204 stimulation (8 Hz for 5 min) at voltage-clamp mode (-70 mV) (*Figure 3A*). The potentiation of  
205 EPSCs reached  $131 \pm 6\%$  of baseline in WT mice ( $t = 38-40$  min;  $n = 13$ ;  $p < 0.001$ ; *Figure 3B*  
206 *and C*), consistent with previous work (*Salin et al., 1996; Kaeser et al., 2008*). Concomitantly,  
207 paired-pulse facilitation (PPF) ratio decreased to  $84 \pm 4\%$  ( $t = 38-40$  min;  $n = 13$ ;  $p < 0.001$ ;  
208 *Figure 3C*), indicating a presynaptic contribution to this form of LTP (*Salin et al., 1996*). Next, we  
209 preincubated WT slices with forskolin for 20 min to ensure the effect of forskolin. In this  
210 condition, the tetanus stimulation for presynaptic LTP failed to induce synaptic potentiation in PCs

211 (Figure 3-figure supplement 1A and B), indicating that presynaptic LTP at PF-PC synapses occurs  
212 upon a rise in the cellular level of cAMP.

213 Next, we examined presynaptic PF-PC LTP in acute slices from *Epac*<sup>dKO</sup> and  
214 *Epac1*<sup>cKO</sup>;*Epac2*<sup>cKO</sup> mice. We made whole-cell recordings from PCs and found that 8-Hz  
215 stimulation failed to induce potentiation of EPSCs in *Epac*<sup>dKO</sup> mice ( $104 \pm 5\%$  of baseline at  $t =$   
216  $38-40$  min;  $n = 11$ ;  $p = 0.66$ ) (Figure 3-figure supplement 1C and D). This finding was confirmed  
217 in recordings from slices of *Epac1*<sup>cKO</sup>;*Epac2*<sup>cKO</sup> mice, in which *Epac* is deleted from the granule  
218 cells innervating the PCs, showing that presynaptic PF-PC LTP was also blocked ( $93 \pm 4\%$  of  
219 baseline at  $t = 38-40$  min;  $n = 9$ ;  $p = 0.059$ ) (Figure 3F and G). In control experiments using  
220 *Math1*-Cre mice, the potentiation of EPSCs reached  $120 \pm 5\%$  of baseline ( $t = 38-40$  min;  $n = 10$ ;  
221  $p = 0.004$ ; Figure 3D and E). These results indicate that presynaptic EPAC is required for  
222 presynaptic LTP.

223 To find out whether presynaptic PKC $\epsilon$  is also required for presynaptic LTP, we recorded 8-Hz  
224 stimulation-induced EPSC potentiation in *Prkce*<sup>ff</sup> and *Prkce*<sup>cKO</sup> mice. Similar to WT and  
225 *Math1*-Cre mice, the potentiation of PF-EPSCs evoked by 8-Hz stimulation reached  $120 \pm 3\%$  of  
226 baseline in control *Prkce*<sup>ff</sup> mice ( $t = 38-40$  min;  $n = 7$ ;  $p = 0.004$ ; Figure 3H and I). However,  
227 presynaptic ablation of PKC $\epsilon$  completely blocked the induction of this form of LTP ( $99 \pm 5\%$ ;  $n =$   
228  $10$ ;  $p = 0.065$ ; Figure 3J and K), suggesting that presynaptic PF-PC LTP also requires PKC $\epsilon$ . Here  
229 too, the PPF ratio was unaffected ( $p = 0.77$  at  $t = 38-40$  min;  $n = 10$ ; Figure 3K). This conclusion  
230 was further confirmed following chemical inhibition of PKC $\epsilon$  by continuously administering  
231  $\epsilon$ V1-2 to cerebellar slices from WT mice, as  $\epsilon$ V1-2 completely blocked the induction of  
232 presynaptic PF-PC LTP ( $101 \pm 4\%$ ;  $n = 9$ ;  $p = 0.59$ ; Figure 3-figure supplement 1E and F).



233 On the basis of our experiments in PCs from mice with presynaptic specific deletion of EPAC  
234 and PKC $\epsilon$ , we conclude that the presynaptic EPAC-PKC $\epsilon$  module is critical for presynaptic PF-PC  
235 LTP in the cerebellum.

236

### 237 **EPAC and PKC $\epsilon$ mediate cAMP-triggered EPSC potentiation**

238 cAMP is also required for presynaptic LTP induced by electrical stimulation (*Salin et al., 1996; Le*  
239 *Guen and De Zeeuw, 2010*), and its agonists are enough to produce a prominent increase in  
240 glutamate release (*Weisskopf et al., 1994; Salin et al., 1996*). However, it remains unclear which  
241 downstream effector, EPAC or PKA (*Cheng et al., 2008*), is responsible for cAMP-induced  
242 potentiation. In particular, the central role of PKA in presynaptic LTP has been argued by studies  
243 showing that presynaptic LTP can still be intact when serine phosphorylation of RIM1 by PKA is  
244 interrupted (*Kaesler et al., 2008; Yang and Calakos, 2010*; also see *Lonart et al., 2003*). Therefore,  
245 we investigated whether the EPAC-PKC $\epsilon$  module mediates cAMP-triggered EPSC potentiation.

246 We made whole-cell recordings from PCs and evoked PF-EPSCs every 30s in *Math1-Cre*,  
247 *Epac1<sup>CKO</sup>;Epac2<sup>CKO</sup>* and *Prkce<sup>CKO</sup>* mice. In *Math1-Cre* control mice, external application of  
248 forskolin produced a long-lasting elevation in PF-EPSC amplitude (*Figure 4A and B*), with a peak  
249 potentiation of  $366 \pm 25\%$  (at 48-50 min;  $n = 15$ ; *Figure 4C*). In contrast, simultaneous ablation of  
250 *Epac1* and *Epac2* at presynaptic sites prominently affected the synaptic potentiation induced by  
251 forskolin application ( $162 \pm 18\%$  at 48-50 min;  $n = 12$ ; *Figure 4A-C*). Next, we incubated  
252 *Epac1<sup>CKO</sup>;Epac2<sup>CKO</sup>* PCs along with PKA antagonist KT5720 and again examined  
253 forskolin-induced EPSC potentiation. In this case, we found that combined blockade of EPAC and  
254 PKA completely eliminated the action of forskolin on EPSC potentiation ( $106 \pm 4\%$  at 48-50 min;

255  $n = 12$ ; *Figure 4A-C*). We continued to examine the effect of PKC $\epsilon$  on cAMP-triggered EPSC  
256 potentiation using *Prkce*<sup>CKO</sup> mice. Similar to *Epac1*<sup>CKO</sup>;*Epac2*<sup>CKO</sup> mice, the forskolin-induced  
257 potentiation in *Prkce*<sup>CKO</sup> PCs was significantly attenuated ( $198 \pm 5\%$  at 48-50 min;  $n = 12$ ; *Figure*  
258 *4A-C*). Again, the remaining potentiation was further blocked by the addition of KT5720 ( $101 \pm 3\%$   
259 at 48-50 min;  $n = 12$ ; *Figure 4A-C*). Thus, these results indicate that EPAC, PKC $\epsilon$  and PKA all  
260 mediate cAMP-induced potentiation of transmitter release. In parallel with the observation of  
261 EPSC amplitude, PPF was monitored during the whole cell recordings. Forskolin application led  
262 to a significant reduction in PPF ratio of PF-EPSCs in *Math1-Cre* mice (*Figure 4C*). However, this  
263 reduction was significantly less when presynaptic of both types of EPAC as well as PKC $\epsilon$  were  
264 ablated and KT5720 was added (*Figure 4C*), further highlighting that EPAC and PKC $\epsilon$  work  
265 synergically on the synaptic release at PF-PC synapses.

266 We next assessed the impact of the EPAC-PKC $\epsilon$  module on the strength of PF-EPSCs by  
267 directly applying EPAC agonist 8-pCPT. In line with previous work (*Kaneko and Takahashi, 2004*;  
268 *Gekel and Neher, 2008*), the administration of 8-pCPT was sufficient to potentiate PF-EPSCs by  
269  $179 \pm 18\%$  and reduce their PPF ratio by  $17 \pm 3\%$  in WT PCs ( $n = 6$ ; at 18-20 min) (*Figure 4D*).  
270 Two lines of evidence confirm that the potentiation of PF-EPSCs by EPAC is mediated by PKC $\epsilon$ .  
271 First, 8-pCPT-induced potentiation of PF-EPSCs was diminished in *Prkce*<sup>CKO</sup> mice, as shown by  
272 unchanged PF-EPSCs and PPF (*Figure 4E*). Second, co-application of  $\epsilon$ V1-2 effectively prevented  
273 the 8-pCPT-induced synaptic potentiation and change in PPF (*Figure 4F*).

274 In summary, we conclude that EPAC-PKC $\epsilon$  module and PKA are both downstream effectors  
275 of cAMP, but the EPAC-PKC $\epsilon$  module plays the most prominent role in cAMP-triggered EPSC  
276 potentiation.

277

278 **Presynaptic EPAC and PKC $\epsilon$  are not involved in postsynaptic forms of plasticity**

279 The mechanisms for postsynaptic LTP and LTD at PF-PC synapses can be complicated, in that  
280 they may depend not only on postsynaptic processes, but sometimes also on presynaptic events  
281 (*Le Guen and De Zeeuw, 2010; Wang et al., 2014; Schonewille et al., 2021*). For example, an  
282 endocannabinoid-triggered reduction of synaptic release is required by the induction of  
283 postsynaptic LTD (*Kreitzer et al., 2002*). As both EPAC and PKC $\epsilon$  regulate Pr of PF-PC synapses,  
284 we wondered whether the EPAC-PKC $\epsilon$  module also regulates postsynaptic LTP and LTD.

285 After acquiring stable EPSCs in voltage-clamp mode (-70 mV), we induced postsynaptic LTP  
286 by stimulating PFs at 1 Hz for 5 min in current-clamp mode (*Figure 5A*). In WT mice, this tetanus  
287 stimulation induced an increase of PF-EPSCs ( $131 \pm 5\%$  of baseline at  $t = 38-40$  min;  $n = 13$ ;  $p <$   
288  $0.001$ ) (*Figure 5B and C*), while PPF was not changed (*Figure 5D*). When this protocol was  
289 applied at PF-PC synapses in *Epac*<sup>dKO</sup> mice, we did not find any sign of potentiation of PF-EPSCs  
290 ( $106 \pm 6\%$  of baseline at  $t = 38-40$  min;  $n = 13$ ;  $p = 0.26$ ) (*Figure 5B-D*). While these results were  
291 consistent with our previous observation that EPAC is required for postsynaptic LTP  
292 (*Gutierrez-Castellanos et al., 2017*), we had yet to specify the cellular site of action for EPAC.  
293 Therefore, we repeated the induction protocol for postsynaptic LTP in *Math1*-Cre and  
294 *Epac1*<sup>cKO</sup>;*Epac2*<sup>cKO</sup> mice. In this case, the protocol successfully induced PF-PC LTP in both types  
295 of mice (*Figure 5E and F*), while PPF was not altered (*Figure 5G*), suggesting that this is a  
296 postsynaptic form of LTP. We continued to examine the expression of postsynaptic PF-PC LTP in  
297 *Prkce*<sup>ff</sup> and *Prkce*<sup>cKO</sup> mice. Similar to *Epac1*<sup>cKO</sup>;*Epac2*<sup>cKO</sup> mice, *Prkce*<sup>ff</sup> and *Prkce*<sup>cKO</sup> PCs  
298 exhibited robust PF-PC LTP when 1 Hz stimulation was delivered to PFs (*Figure 5H and I*) with

299 unaltered PPF (*Figure 5J*), confirming the postsynaptic site of LTP.

300       Next, we investigated whether the expression of postsynaptic PF-PC LTD is affected by  
301 ablation of EPAC and PKC $\epsilon$ . PF-PC LTD was induced by giving repetitive PF stimulation at 100  
302 Hz for 100 ms paired with a depolarization of the PCs involved (*Figure 6A*) (*Steinberg et al., 2006*;  
303 *Zhou et al., 2015*). As shown by example responses (*Figure 6B*), *Epac*<sup>dKO</sup> PCs showed robust  
304 PF-PC LTD (t = 38-40 min: 59  $\pm$  4% of baseline; n = 13; *Figure 6C*), while the PPF ratio was not  
305 changed (p = 0.26 at t = 38-40 min; n = 13; *Figure 6D*). Likewise, PF-PC LTD could be  
306 successfully induced in *Math1-Cre* and *Epac1*<sup>cKO</sup>;*Epac2*<sup>cKO</sup> mice (*Figure 6E and F*), while PPF  
307 was not altered (*Figure 6G*). Moreover, we found that the same protocol could induce PF-PC LTD  
308 in *Prkce*<sup>fl/fl</sup> and *Prkce*<sup>cKO</sup> mice (*Figure 6H and I*) without affecting PPF (*Figure 6J*).

309       Overall, our results suggest that presynaptic EPAC and PKC $\epsilon$  are not required for the  
310 induction of postsynaptic forms of LTP and LTD.

311

### 312 **The EPAC-PKC $\epsilon$ module is essential for motor performance and motor learning**

313       Even though plastic changes in the granular layer of the cerebellum have been suggested to  
314 contribute to procedural memory formation (*Le Guen and De Zeeuw, 2010*), the evidence thus far  
315 is limited (*Andreescu et al., 2011; Galliano et al., 2013*). Therefore, we investigated whether the  
316 EPAC-PKC $\epsilon$  module, which is critical to presynaptic PF-PC LTP, contributes to performance and  
317 adaptation of compensatory eye movements mediated by the vestibulo-cerebellum (*Schonewille et*  
318 *al., 2010; Grasselli et al., 2020*).

319       Basic performance parameters included amplitude (gain) and timing (phase) of the  
320 optokinetic response (OKR), vestibulo-ocular reflex (VOR), and visually enhanced VOR (VVOR)

321 (Figure 7A). We found that basic motor performance was impaired in *Epac*<sup>dkO</sup> mice in that they  
322 showed significant deficits in the amplitude and timing of their OKR ( $p = 0.009$  and  $p = 0.004$ ,  
323 respectively; ANOVA for repeated measurements) and VOR ( $p = 0.001$  and  $p = 0.02$ , respectively;  
324 ANOVA for repeated measurements) (Figure 7-figure supplement 1A and B). In contrast, no  
325 significant differences were observed in the VVOR ( $p = 0.66$  and  $p = 0.68$  for gain and phase  
326 values, respectively; Figure 7-figure supplement 1C).

327 The same compensatory eye movements were also tested in *Epac1*<sup>ckO</sup>;*Epac2*<sup>ckO</sup> and *Prkce*<sup>ckO</sup>  
328 mice as well as their littermate controls. Basic eye movement performance was also affected in  
329 *Epac1*<sup>ckO</sup>;*Epac2*<sup>ckO</sup> mice in that their OKR gains were significantly lower than those of  
330 *Math1*-Cre littermates ( $p = 0.003$ ; ANOVA for repeated measurements) (Figure 7B), that their  
331 VOR gains were significantly greater than those of *Math1*-Cre littermates (VOR:  $p = 0.027$ ;  
332 ANOVA for repeated measurements) (Figure 7C), and that the phase values during both OKR and  
333 VOR were significantly lagging those of the *Math1*-Cre littermates (OKR:  $p = 0.001$ ; VOR:  $p =$   
334  $0.047$ ; ANOVA for repeated measurements) (Figure 7B and C). No significant differences were  
335 observed between *Epac1*<sup>ckO</sup>;*Epac2*<sup>ckO</sup> and *Math1*-Cre mice in the VVOR ( $p = 0.69$  and  $p = 0.75$   
336 for gain and phase values, respectively) (Figure 7D). Moreover, *Prkce*<sup>ckO</sup> mice shared the same  
337 defects with *Epac1*<sup>ckO</sup>;*Epac2*<sup>ckO</sup> mice in their basic motor performance. OKR gain values of  
338 *Prkce*<sup>ckO</sup> mice were significantly lower than those of *Prkce*<sup>ff</sup> littermates ( $p = 0.013$ ; ANOVA for  
339 repeated measurements) (Figure 7E), whereas their VOR gain values were greater than those of  
340 control littermates ( $p = 0.034$ ; ANOVA for repeated measurements) (Figure 7F). Meanwhile, OKR  
341 and VOR phase values of *Prkce*<sup>ckO</sup> mice were both significantly lagging those of the *Math1*-Cre  
342 littermates (OKR:  $p = 0.015$ ; VOR:  $p = 0.044$ ; ANOVA for repeated measurements) (Figure 7E

343 and *F*). No significant differences were observed between *Prkce<sup>ff</sup>* and *Prkce<sup>ckO</sup>* mice in the  
344 VVOR ( $p = 0.93$  and  $p = 0.50$  for gain and phase values, respectively) (*Figure 7G*). Altogether,  
345 our data suggest that presynaptic ablation of EPAC and/or PKC $\epsilon$  mice profoundly influences  
346 motor performance when visual and vestibular systems are separated, but not when they are  
347 engaged simultaneously, as occurs under natural conditions or during visuo-vestibular training.

348 Next, we tested the VOR phase-reversal protocol, which is considered the type of motor  
349 learning sensitive to the perturbation to the vestibulo-cerebellum (*Wulff et al., 2009; Badura et al.,*  
350 *2016; Peter et al., 2016*). VOR phase reversal aims to reverse the direction of the VOR using  
351 retinal slip caused by a screen rotation in the same direction (i.e., in phase) as head rotation and  
352 with increasing amplitude as the training progresses (*Figure 7H*). During the initial days of  
353 gain-decrease training, all three control mouse lines (WT, *Math1-Cre* and *Prkce<sup>ff</sup>*) exhibited gain  
354 reductions similar to previous work (*Wulff et al., 2009; Badura et al., 2016; Gutierrez-Castellanos*  
355 *et al., 2017*). Gain reductions were smaller in *Epac<sup>dkO</sup>* (*Figure 7-figure supplement 1D*),  
356 *Epac1<sup>ckO</sup>;Epac2<sup>ckO</sup>* (*Figure 7I*), as well as *Prkce<sup>ckO</sup>* (*Figure 7J*) mice, but the deficit varied across  
357 days between the different mouse lines (in *Epac<sup>dkO</sup>* mice, Day 1:  $p = 0.043$ ; Day 2:  $p = 0.008$ ; Day  
358 3:  $p = 0.002$ ; Day 4:  $p = 0.007$ ; Day 5:  $p = 0.004$ ; in *Epac1<sup>ckO</sup>;Epac2<sup>ckO</sup>* mice, Day 1:  $p = 0.079$ ;  
359 Day 2:  $p = 0.036$ ; Day 3:  $p = 0.011$ ; Day 4:  $p = 0.22$ ; Day 5:  $p = 0.061$ ; and in *Prkce<sup>ckO</sup>* mice, Day  
360 1:  $p = 0.047$ ; Day 2:  $p = 0.004$ ; Day 3:  $p = 0.004$ ; Day 4:  $p = 0.084$ ; Day 5:  $p = 0.15$ ). WT (*Figure*  
361 *7-figure supplement 1D*), *Math1-Cre* (*Figure 7I*) as well as *Prkce<sup>ff</sup>* (*Figure 7J*) mice showed a  
362 proper reversal of the phase of their VOR, highlighting their ability to invert the direction of an  
363 innate reflex (*Wulff et al., 2009; Badura et al., 2016; Peter et al., 2016; Grasselli et al., 2020*).  
364 Whereas the VOR phase values were not significantly affected in the *Epac<sup>dkO</sup>*,

365 *Epac1<sup>ckO</sup>;Epac2<sup>ckO</sup>*, and *Prkce<sup>ckO</sup>* mouse lines during the first day (WT versus *Epac<sup>dkO</sup>*,  $p = 0.15$ ;  
366 *Math1-Cre* versus *Epac1<sup>ckO</sup>;Epac2<sup>ckO</sup>*,  $p = 0.087$ ; *Prkce<sup>ff</sup>* versus *Prkce<sup>ckO</sup>*,  $p = 0.52$ ), they were so  
367 during sessions on days 2-5 (WT versus *Epac<sup>dkO</sup>*: Day 2,  $p = 0.003$ ; Day 3,  $p = 0.002$ ; Day 4,  $p <$   
368  $0.001$ ; Day 5,  $p < 0.001$ ; *Math1-Cre* versus *Epac1<sup>ckO</sup>;Epac2<sup>ckO</sup>*: Day 2,  $p < 0.001$ ; Day 3,  $p <$   
369  $0.001$ ; Day 4,  $p < 0.001$ ; Day 5,  $p < 0.001$ ; *Prkce<sup>ff</sup>* versus *Prkce<sup>ckO</sup>*: Day 2,  $p = 0.01$ ; Day 3,  $p =$   
370  $0.048$ ; Day 4,  $p < 0.001$ ; Day 5,  $p < 0.001$ ). Therefore, we conclude that *Epac<sup>dkO</sup>*,  
371 *Epac1<sup>ckO</sup>;Epac2<sup>ckO</sup>* and *Prkce<sup>ckO</sup>* mice had prominent deficits in phase-reversal learning of their  
372 VOR.

373 **Discussion**

374 In the current study we demonstrate that triggering EPAC induces PKC $\epsilon$  activation and threonine  
375 phosphorylation of RIM1 $\alpha$ , which in turn facilitates the assembly of the Rab3A-RIM1 $\alpha$ -Munc13-1  
376 tripartite complex and thereby docking and release of synaptic vesicles at active zones of PF-PC  
377 synapses (*Figure 7-figure supplement 2*). The form of presynaptic LTP at these synapses that  
378 requires activation of the EPAC-PKC $\epsilon$  module can be induced by either tetanic stimulation or  
379 forskolin at PF terminals (*Figure 7-figure supplement 2*). Via its presynaptic actions, the  
380 EPAC-PKC $\epsilon$  module contributes to adaptation of compensatory eye movements, a motor learning  
381 task that depends on the vestibule-cerebellum.

382

383 **Threonine phosphorylation of RIM1 $\alpha$  by the EPAC-PKC $\epsilon$  module**

384 Our finding that the EPAC-PKC $\epsilon$  module can phosphorylate RIM1 $\alpha$  raises a simple but  
385 fascinating mechanistic concept that the phosphorylation level of RIM1 $\alpha$  determines presynaptic  
386 release. RIM1 $\alpha$  specifically interacts with a number of presynaptic proteins, such as Munc13-1,  
387 liprin- $\alpha$  and ELKS, so as to form a scaffold complex regulating homeostatic release of synaptic  
388 vesicles (*Südhof, 2004*). RIM1 $\alpha$  can be phosphorylated at two serine residues by PKA and  
389 CaMKII (*Lonart et al., 2003; Sun et al., 2003*), which promotes its interaction with 14-3-3 protein  
390 (*Sun et al., 2003*). The current work advances on this concept by showing that RIM1 $\alpha$  can also be  
391 phosphorylated at its threonine sites by PKC $\epsilon$ . Moreover, our data demonstrate the functional  
392 implication consequence of threonine phosphorylation of RIM1 $\alpha$  at PF-PC synapses: it promotes  
393 the assembly of the Rab3A-RIM1 $\alpha$ -Munc13-1 complex and is essential for the induction of  
394 presynaptic PF-PC LTP, suggesting that a fast switch between phosphorylation and



395 dephosphorylation of RIM1 $\alpha$  may regulate presynaptic potentials during dynamic synaptic events.

396 This new mechanistic concept is in line with the notion that synaptic vesicle proteins, such as

397 RIM1 $\alpha$ , often exhibit stimulation-dependent changes in phosphorylation (*Kohansal-Nodehi et al.,*

398 *2016*). It remains to be elucidated how threonine and serine phosphorylations of RIM1 $\alpha$  may exert

399 distinct downstream effects. For instance, one could speculate that the threonine loci of RIM1 $\alpha$

400 lead to more prominent conformational changes, allowing RIM1 $\alpha$  to bind to active zone proteins.

401

#### 402 **Distinct roles of EPAC and PKA at synapses**

403 cAMP-mediated signaling pathways that are mediated by EPAC and PKA regulate a multitude of

404 physiological and pathological processes (*Cheng et al., 2008*). EPAC shares homologous

405 cAMP-binding domains with PKA, but also possesses domains absent in PKA, such as the Ras

406 exchange motif, the Ras association domain, and the CDC25-homology domain (*Cheng et al.,*

407 *2008*). Indeed, the specific domains endow EPAC and PKA with different and even opposite

408 functions. For example, in contrast to PKA, EPAC can activate small GTPase Rap1 (*de Rooij et*

409 *al., 1998*) and increase PKB phosphorylation (*Mei et al., 2002*). Our current work bolsters the

410 differences, showing that EPAC can phosphorylate PKC $\epsilon$  and RIM1 $\alpha$  threonine sites at synapses.

411 This highlights the question as to how EPAC and PKA operate in an integrated manner to control

412 the net physiological effect of cAMP-signaling pathways at synapses. Some studies indicate that

413 presynaptic potentiation depends predominantly on PKA (*Salin et al., 1996; Linden and Ahn, 1999;*

414 *Lev-Ram et al., 2002*), whereas others advocate a more critical role for EPAC (*Kaneko and*

415 *Takahashi, 2004; Fernandes et al., 2015; Martín et al., 2020*). Our results highlight that ablation

416 of either EPAC or PKC $\epsilon$  by itself is not sufficient to block forskolin-induced synaptic potentiation,

417 but that supplementing this with a blockage of PKA causes a complete blockage. These results  
418 demonstrate that EPAC and PKA can conjunctively regulate synaptic potentiation. Even so, our  
419 results clarify that the impact of EPAC on cAMP-induced EPSC potentiation is dominant, as it has  
420 the strongest contribution to the forskolin-induced increase of EPSC amplitude. Alternatively,  
421 PKA warrants a minimum level of potentiation that may be required under particular  
422 circumstances when EPAC is not active.

423

#### 424 **The EPAC-PKC $\epsilon$ module is required for synaptic release and presynaptic LTP**

425 Our EM analysis shows that the number of docked vesicles at the PF terminals of *Epac*<sup>dKO</sup> and  
426 *Prkce*<sup>cKO</sup> mutants is reduced, whereas the general structure of PF-PC synapses is unchanged. As  
427 the ablation of either EPAC or PKC $\epsilon$  attenuated protein interactions in the  
428 Rab3A-RIM1 $\alpha$ -Munc13-1 complex, which is required for the docking and priming of presynaptic  
429 vesicles (*Schoch et al. 2002; Südhof, 2004; Ferrero et al., 2013*), the reduction in docked vesicles  
430 in *Epac*<sup>dKO</sup> and *Prkce*<sup>cKO</sup> mice can be readily explained. In parallel with our observations at the  
431 ultrastructural level, we found that mice with presynaptic deletion of *Epac* and *Prkce*<sup>cKO</sup> displayed  
432 obvious defects in synaptic release at the electrophysiological level. Although EPAC1 and EPAC2  
433 have been shown to be involved in synaptic release in the hippocampus and cerebellum (*Yang et*  
434 *al., 2012; Zhao et al., 2013; Martín et al., 2020*), our finding that PKC $\epsilon$  acts as the downstream  
435 effector of EPAC and regulates presynaptic release is novel. Furthermore, we demonstrate for the  
436 first time that presynaptic PKC $\epsilon$  is required for presynaptic LTP at PF-PC synapses. These  
437 findings expand the repertoire of forms of PC plasticity that are driven by cAMP signaling.

438 The role of the cAMP-PKA cascade in presynaptic LTP has been extensively debated. Early

439 studies claimed that PKA and RIM1 $\alpha$  serine phosphorylation are critical for the induction of  
440 presynaptic LTP at PF-PC synapses (*Salin et al., 1996; Lonart et al., 2003*). However, this  
441 conclusion was challenged by follow-up studies, demonstrating that RIM1 $\alpha$  S413A mutant mice  
442 exhibit normal presynaptic LTP in both cerebellum and hippocampus (*Kaesler et al., 2008; Yang  
443 and Calakos, 2010*). In our opinion, a couple of caveats must be considered regarding the function  
444 of PKA in presynaptic LTP. First, cAMP analogs (Rp-8-CPT-cAMP-S and Sp-8CPT-cAMP-S)  
445 used in two studies advocating that PKA mediates presynaptic PF-PC LTP (*Salin et al., 1996;  
446 Lonart et al., 2003*) are able to regulate Rap1 (*Roscioni et al., 2009*), which is a direct substrate of  
447 EPAC (*de Rooij et al., 1998*). Therefore, these cAMP analogs may also act through the  
448 EPAC-PKC $\epsilon$  module. Second, KT5720 at 10  $\mu$ M, a concentration used by Lonart et al. (*Lonart et  
449 al., 2003*), can alter a range of protein kinases, including phosphorylase kinase, mitogen-activated  
450 protein kinase kinase, PKB $\alpha$ , glycogen synthase kinase 3 $\beta$ , as well as AMP-activated protein  
451 kinase (*Brushia and Walsh, 1999; Davies et al., 2000; Murray, 2008*). Thus, KT5720 at this  
452 concentration has numerous side-effects next to its ability to inhibit PKA. In contrast, our results  
453 derived from cell-specific mouse lines consistently converge on the concept that presynaptic  
454 PF-PC LTP depends on the EPAC-PKC $\epsilon$  module. More specifically, our data demonstrate that  
455 repetitive 8-Hz PF stimulation increases the level of cAMP and consequently activates EPAC and  
456 PKC $\epsilon$ , which in turn induces threonine phosphorylation of RIM1 $\alpha$ , suggesting a phospho-switch  
457 machinery that can tune presynaptic PF-PC LTP.

458 Our finding that the EPAC-PKC $\epsilon$  module is a central component for synaptic release and  
459 presynaptic LTP may not stand on its own. In fact, EPAC is involved in cellular processes like cell  
460 adhesion, cell-cell junction formation, exocytosis and secretion, cell differentiation, as well as cell

461 proliferation (*Cheng et al., 2008*), while PKC $\epsilon$  is necessary for sperm exocytosis in the testis  
462 (*Lucchesi et al., 2016*). Together, these lines of evidence suggest that the EPAC-PKC $\epsilon$  module  
463 might be a widespread mechanism controlling not only synaptic release in nerve cells, but also  
464 granule secretion in endocrine or proliferating cells.

465

#### 466 **Role of presynaptic LTP in motor behavior**

467 Many studies have explored the potential functional role of postsynaptic plasticity at PC synapses,  
468 in particular that of PF-PC LTP and PF-PC LTD (*Gao et al., 2012; Raymond and Medina, 2018*).  
469 The picture emerging from these studies is that postsynaptic PF-PC LTP and PF-PC LTD play an  
470 important role in forms of learning that are mediated by the so-called upbound and downbound  
471 modules (*De Zeeuw, 2021*). Whereas VOR adaptation is mainly mediated by upbound microzones  
472 in the vestibulo-cerebellum that increase the simple spike frequency during learning  
473 (*Gutierrez-Castellanos et al., 2017; Voges et al., 2017*), eyeblink conditioning is predominantly  
474 regulated by downbound microzones in lobule simplex that decrease simple spikes during learning  
475 (*Ten Brinke et al., 2015; Wu et al., 2019*). Yet, what is the role of presynaptic LTP at PF to PC  
476 synapses? Even though it has been suggested more than a decade ago that the functional role of  
477 presynaptic plasticity at PF-PC synapses during learning can be expected to align with that of  
478 postsynaptic plasticity (*Le Guen and De Zeeuw, 2010*), evidence has been largely lacking.

479       Here, we found that *Epac1*<sup>ckO</sup>; *Epac2*<sup>ckO</sup> and *Prkce*<sup>ckO</sup> mice, which showed reduced PF-PC  
480 transmission and lack presynaptic LTP, exhibit deficits in basic motor performance, in the form of  
481 an affected OKR and VOR, as well as in gain-decrease and phase reversal learning of their VOR  
482 (*Figure 7–figure supplement 2*). Similarly, presynaptic ablation of EPACs or PKC $\epsilon$  results in

483 altered gain and phase values of their OKR and VOR. Interestingly, the impairments in OKR and  
484 VOR caused by deletion of *Epac1/Epac2* or *Prkce* in granule cells were similar to those caused by  
485 global deletion of *Epac*. This finding raises the possibility that presynaptic EPAC is in fact more  
486 critical for basic motor performance than postsynaptic EPAC. This possibility is compatible with  
487 previous work showing that mice with a PC-specific deletion of GluA3, which leads to a lack of  
488 postsynaptic LTP mediated by EPAC, have hardly any significant deficit in basic motor  
489 performance (*Gutierrez-Castellanos et al., 2017*). By the same argument, the contribution of  
490 presynaptic LTP to phase reversal learning might be more in line with that of postsynaptic PF-PC  
491 LTP in that *Epac1<sup>CKO</sup>;Epac2<sup>CKO</sup>* and *Prkce<sup>CKO</sup>* mice showed similar deficits as PC-specific GluA3  
492 knockouts. The prediction that the impact of presynaptic plasticity at PF-PC synapses during  
493 learning operates in a synergistic fashion with that of postsynaptic plasticity (*Le Guen and De*  
494 *Zeeuw, 2010*), does in this respect hold.

## 495 **Materials and Methods**

### 496 **Animals**

497 Original breeding pairs of *Epac*<sup>dKO</sup> and *Math1*-Cre mice were obtained from Youmin Lu  
498 (Huazhong University of Science and Technology, Wuhan, China) and Wei Mo (Xiamen  
499 University, Xiamen, China), respectively. *Epac1*<sup>ff</sup>, *Epac2*<sup>ff</sup> and *Prkce*<sup>ff</sup> mice were made by us  
500 with the assistance of GemPharmatech (Soochow, Jiangsu, China) and Nanjing Biomedical  
501 Research Institute (Nanjing, Jiangsu, China). The resulting offspring were genotyped using PCR  
502 of genomic DNA. Mice were kept at the Experimental Animal Center of Zhejiang University  
503 under temperature-controlled condition on a 12:12 h light/dark cycle. All experiments were  
504 performed blind to genotypes in age-matched littermates of either sex.

505

### 506 **Antibodies and Reagents**

507 Antibodies against RIM1 (Cat# 140013, RRID:AB\_2238250 and Cat# 140023,  
508 RRID:AB\_2177807), Rab3 (Cat# 107011, RRID:AB\_887768) and Munc13-1 (Cat# 126102,  
509 RRID:AB\_887734) were from Synaptic Systems (Gottingen, Germany). Antibodies against  
510 phosphor-threonine (Cat# 9381, RRID:AB\_330301), EPAC1 (Cat# 4155, RRID:AB\_1903962)  
511 and EPAC2 (Cat# 4156, RRID:AB\_1904112) were from Cell Signaling (Danvers, MA). The  
512 antibody to phosphor-serine (Cat# AB1603, RRID:AB\_390205) was from Millipore (Billerica,  
513 MA). Antibodies against HA (Cat# M20003, RRID:AB\_2864345), Flag (Cat# M20008,  
514 RRID:AB\_2713960) and His (Cat# M30111, RRID:AB\_2889874) were from Abmart (Shanghai,  
515 China). Antibody against PKC $\alpha$  (Cat# P4334, RRID:AB\_477345) was from sigma (St. Louis,  
516 MO). Antibodies against PKC $\alpha$ -pS657 (ab23513, RRID:AB\_2237450), PKC $\alpha$ -pT638 (Cat#

517 ab32502, RRID:AB\_777295), PKC $\epsilon$ -pSer729 (Cat# ab63387, RRID:AB\_1142277), EPAC1 (Cat#  
518 ab21236, RRID:AB\_2177464, for immunostaining), EPAC2 (Cat# ab124189,  
519 RRID:AB\_10974926, for immunostaining), anti-mouse IgG for IP (HRP) (Cat# ab131368,  
520 RRID:AB\_2895114) and VeriBlot for IP Detection Reagent (HRP) (Cat# ab131366,  
521 RRID:AB\_2892718) were from Abcam (Cambridge, UK). Antibody against  $\beta$ -tubulin (Cat#  
522 sc-5274, RRID:AB\_2288090) was from Santa Cruz (Dallas, TX). Antibody against PKC $\epsilon$  (Cat#  
523 MA5-14908, RRID:AB\_10985232), Goat anti-mouse IgG horseradish peroxidase  
524 (HRP)-conjugated (Cat# 31446, RRID:AB\_228318), Goat anti-rabbit IgG horseradish peroxidase  
525 (HRP)-conjugated (Cat# 31460, RRID:AB\_228341) were from Thermo Fisher Scientific  
526 (Waltham, MA). Anti-vGluT1 antibody was a gift from Dr. Masahiko Watanabe (Hokkaido  
527 University, Sapporo, Japan). The antibody against PKC $\epsilon$  (Cat# 20877-1-AP, RRID:AB\_10697812,  
528 for immunostaining) was from Proteintech (Rosemont, IL). Mouse IgG (Cat# A7028,  
529 RRID:AB\_2909433) and rabbit IgG (Cat# A7016, RRID:AB\_2905533) were from Beyotime  
530 (Shanghai, China). Protease inhibitor cocktail (04693132001) was from Roche (Mannheim,  
531 Germany). Gö6976 (2253), 8-pCPT (4853) and FR236924 (3091) were from Tocris (Bristol, UK).  
532 Dulbecco's modified Eagle's medium (DMEM, 11885-084), Penicillin-Streptomycin (15140-122),  
533 Sodium Pyruvate (11360-070), Fetal Bovine Serum (FBS, 10099-133), lipofectamine 2000  
534 (11668-019), OPTI-MEM (31985-062), and Alexa Fluor-conjugated secondary antibodies were  
535 from Invitrogen (Carlsbad, CA). GammaBind Plus Sepharose (17-0886-01) was from GE  
536 healthcare. Other chemicals were from Sigma (St. Louis, MO) unless stated otherwise.

537

538 **Plasmid construction**

539 The construction of plasmids was performed according to previous work (*Wang et al., 2015*).  
540 HA-RIM1 $\alpha$ , Flag-EPAC1, Flag-EPAC2, and His-PKC $\epsilon$ , were constructed based on the coding  
541 sequence of rat *RIM1a* gene (GenBank# NM\_052829.1), rat *EPAC1* gene (GenBank#  
542 NM\_021690.1), rat *EPAC2* gene (GenBank# XM\_017592164.1), and rat *Prkce* gene (GenBank#  
543 NM\_017171.1), respectively. All constructs were verified by DNA sequencing.

544

#### 545 **RT-PCR**

546 RT-PCR was used to determine the mRNA level of EPAC1, EPAC2 and PKC $\epsilon$  in granule cells.  
547 The contents of individual granule cells (P21) were harvested as described in previous work (*Zhou*  
548 *et al., 2017*). The harvested contents were subjected to RT-PCR using OneStep Kit (210212,  
549 Qiagen, Hilden, Germany). Forward (F) and reverse (R) primers used for amplification were as  
550 follows: *Epac1*, F: 5'- GCT TGT TGA GGC TAT GGC-3'; R: 5'- ACA CAG TTC CTG CCT  
551 TGC-3'. *Epac2*, F: 5'- CAT TCT CTC TCG AGC TCC-3'; R: 5' TGG TTG AGG ACA CCA  
552 TCT-3'. *Prkce*, F: 5'- ATT GAC CTG GAG CCA GAA -3'; R: 5'- CTT GTG GCC ATT GAC  
553 CTG-3'. *Gapdh*, F: 5'-GGT GAA GGT CGG TGT GAA CG-3'; R: 5'-CTC GCT CCT GGA AGA  
554 TGG TG-3'.

555

#### 556 **HEK cell culture**

557 HEK cells were cultured in DMEM supplemented with 10% FBS, 1 mM sodium pyruvate, 100  
558 U/ml penicillin, and 10  $\mu$ g/ml streptomycin and stored in an incubator (95% O<sub>2</sub>/5% CO<sub>2</sub>; 37°C).  
559 The plasmids were transfected to HEK cells in OPTI-MEM using lipofectamine 2000 (Invitrogen)  
560 at 70-80% confluency.



561

562 **Purification of synaptosomes**

563 Synaptosomes were purified according to previous work (*Ferrero et al., 2013*). Cerebellar tissues  
564 from mice (P21) were homogenized in a medium (pH7.4) containing sucrose (320 mM) and  
565 protease inhibitors. The homogenate was centrifuged  $2,000\times g$  ( $4^{\circ}\text{C}$  for 2 min) and the supernatant  
566 was spun again at  $9,500\times g$  ( $4^{\circ}\text{C}$  for 12 min). The compacted white layer containing the majority  
567 of synaptosomes was gently resuspended in sucrose (320 mM) supplemented with protease  
568 inhibitors, and an aliquot of synaptosomal suspension (2 ml) was placed onto a 3-ml Percoll  
569 discontinuous gradient (GE Healthcare) containing (in mM) 320 sucrose, 1 EDTA, 0.25  
570 DL-dithiothreitol, and 3, 10, or 23% Percoll. After centrifugation at  $25,000\times g$  ( $4^{\circ}\text{C}$  for 10 min),  
571 synaptosomes were recovered from between 10% and 23% bands and diluted in a medium (in mM)  
572 (140 NaCl, 5 KCl, 5  $\text{NaHCO}_3$ , 1.2  $\text{NaH}_2\text{PO}_4$ , 1  $\text{MgCl}_2$ , 10 glucose, 10 HEPES; pH 7.4)  
573 supplemented with protease inhibitors. The synaptosomes good for experiments were harvested  
574 from the pellet after the final centrifugation at  $22,000\times g$  ( $4^{\circ}\text{C}$  for 10 min).

575

576 **Immunocytochemistry**

577 For immunocytochemistry, synaptosomes were added to a medium containing 0.32 M sucrose (pH  
578 7.4), allowed to attach to polylysine-coated coverslips for 1 h, and fixed for 10 min in 4%  
579 paraformaldehyde in 0.1 M phosphate buffer (PB) (pH 7.4) at room temperature. Following  
580 several washes with PB (pH 7.4), synaptosomes were incubated for 1 h in 10% normal goat serum  
581 diluted in PBS (pH 7.4) containing 0.2% Triton X-100. Subsequently, they were incubated for 24  
582 h with primary antiserum for EPAC1 (1:500), EPAC2 (1:500),  $\text{PKC}\epsilon$  (1:500) and vGluT1 (1:500).

583 After washing in PBS, synaptosomes were incubated with secondary antibodies for 2 h.  
584 Coverslips were mounted with Prolong Antifade Kit (Molecular Probes) and synaptosomes were  
585 viewed using a confocal microscope (Nikon A1R) with a  $\times 100$  objective.

586

#### 587 **Co-immunoprecipitation**

588 After measuring protein concentration using the BCA assay, a tenth of lysis supernatant derived  
589 from synaptosomes or cultured cells was used for input and the remainder were incubated with  
590 anti-RIM1 or anti-HA antibody, which was precoupled to GammaBind Plus Sepharose at 5-10  $\mu\text{g}$   
591 antibody/1 ml beads for 3 h. Proteins on the beads were extracted with 2 $\times$  SDS sample buffer plus  
592 protease inhibitors and boiled for 5 min before Western blot.

593

#### 594 **Western blotting**

595 The protein concentration was determined using BCA protein assay. Equal quantities of proteins  
596 were loaded and fractionated on SDS-PAGE, transferred to PVDF membrane (Immobilon-P,  
597 Millipore), immunoblotted with antibodies, and visualized by enhanced chemiluminescence  
598 (Thermo). The dilutions of primary antibodies were 1:1,000 for RIM1, Munc13-1, PKC $\alpha$ -pS657,  
599 EPAC1, EPAC2, p-Thr, p-Ser,  $\beta$ -tubulin, and PKC $\epsilon$ -pSer729; 1:2,000 for Rab3A and PKC $\epsilon$ ;  
600 1:5,000 for PKC $\alpha$ -pT638; 1:10,000 for HA, His, Flag, GAPDH, and PKC $\alpha$ . Secondary antibodies  
601 were goat anti-rabbit (1:10,000), goat anti-mouse (1:10,000), anti-mouse IgG for IP (HRP)  
602 (1:1,000), VeriBlot for IP Detection Reagent (HRP) (1:1,000). Film signals were digitally scanned  
603 and quantified using ImageJ 1.42q (NIH, Bethesda, MD).

604

605 **Electron microscopy**

606 After anesthetic mice (P21) were transcardially perfused with saline and ice-cold fixative, brains  
607 were removed and stored at 4°C for 2.5 h in fixative. Sagittal slices of vermis (200 µm) were  
608 prepared and rectangular molecular layer sections from lobules IV-V were dissected. The samples  
609 were dehydrated and embedded in an epoxy resin. Ultrathin sections (90 nm) were cut using an  
610 ultra-microtome (Leica), stained with 2% uranyl acetate and lead solution, and mounted on grids.  
611 EM images were captured at 30,000× magnification using a Tecnai transmission electron  
612 microscope (FEI, Hillsboro, OR). PF-PC synapses were identified by asymmetrical and short  
613 contacts, which were distinct from GABAergic or climbing fiber synapses (*Ichikawa et al., 2016*).  
614 ImageJ was used to count the numbers of total and docked vesicles per bouton.

615

616 **Golgi staining and spine density analysis**

617 Golgi staining was performed using Rapid Golgi Stain Kit (FD NeuroTech Inc., Ellicott, MD)  
618 according to the manufactory's instruction. PCs at the apical region were imaged using a bright  
619 field microscope (Zeiss, Germany). ImageJ was used to count the spine number and dendrites  
620 length of PCs with manual assistant.

621

622 **Electrophysiology**

623 Sagittal slices of cerebellar vermis (250 µm) were prepared from anesthetic mice (P21) using a  
624 vibrating tissue slicer (Leica VT1000S) and ice-cold standard artificial cerebrospinal fluid (aCSF)  
625 containing (in mM): 125 NaCl, 2.5 KCl, 1.25 NaH<sub>2</sub>PO<sub>4</sub>, 1 MgCl<sub>2</sub>, 2 CaCl<sub>2</sub>, 26 NaHCO<sub>3</sub> and 25  
626 D-glucose, bubbled with 95% O<sub>2</sub>/5% CO<sub>2</sub>. After recovery for 30 min at 37°C, slices were placed

627 in a submerged chamber that was perfused at 2 ml/min with aCSF supplemented with GABAzine  
628 (10  $\mu$ M) during recordings.

629 PCs were visualized under an upright microscope (BX51, Olympus) equipped with a 40 $\times$   
630 water-immersion objective and infrared differential interference contrast enhancement. Whole-cell  
631 recordings were made on PCs from lobules IV-V with a MultiClamp 700B amplifier (Molecular  
632 Devices). Currents were digitized at 10 kHz and filtered at 3 kHz. Patch electrodes (3-5 M $\Omega$ ) were  
633 filled with an intracellular solution containing (in mM) 135 Cs-methanesulfonate, 10 CsCl, 10  
634 HEPES, 0.2 EGTA, 4 Na<sub>2</sub>ATP, and 0.4 Na<sub>3</sub>GTP (pH 7.3, OSM 290). PCs were held at -70 mV to  
635 prevent spontaneous spikes that might escape clamp. For PF stimulation, standard patch pipettes  
636 were filled with aCSF and placed in middle third of molecular layer. Presynaptic PF-PC LTP was  
637 induced by stimulating PF input 120 times at 8 Hz (*Salin et al., 1996; Kaeser et al., 2008*).  
638 Postsynaptic PF-PC LTP was obtained when PFs were stimulated at 1 Hz for 5 min in parallel  
639 with current-clamp of recording PC (*Wang et al., 2014*). PF-LTD was induced by a conjunction of  
640 5 PF-pulses at 100 Hz and a 100-ms long depolarization of PC to 0 mV, which was repeated 30  
641 times with an interval of 2 s (*Zhou et al., 2015*). mEPSCs were recorded in whole-cell  
642 configuration in the presence of tetrodotoxin (0.5  $\mu$ M) and an offline analysis was conducted using  
643 a sliding template algorithm (ClampFit 10, Molecular Device) according to previous work (*Zhou*  
644 *et al., 2017*). To estimate the RRP size and release Pr, a repeated 20 Hz train stimulation protocol  
645 was used to evoke 40 EPSCs. The RRP size was calculated by linear interpolating the linear  
646 portion of the cumulative EPSC amplitude plot to virtual stimulus 0. The release Pr was calculated  
647 as the mean amplitude of the 1st EPSC during the repeated train stimulations divided by the RRP  
648 size (*He et al., 2019*).

649

650 **Compensatory eye movement test**

651 Mice (P60) were surgically prepared for head-restrained recordings of compensatory eye  
652 movements. A pedestal was attached to the skull after shaving and opening the skin overlaying it,  
653 using Optibond primer and adhesive (Kerr, Bioggio, Switzerland) and under isoflurane anesthesia  
654 in O<sub>2</sub> (induction with 4% and maintained at 1.5% concentration). Mice were administered  
655 xylocaine and an injection with bupivacaine hydrochloride (2.5 mg/ml, bupivacaine actavis) to  
656 locally block sensation. The pedestal consisted of a brass holder (7 × 4 mm base plate) with a  
657 neodymium magnet (4 × 4 × 2 mm) and a screw hole for fixation. After a recovery period of at  
658 least 3 days, mice were placed in a mouse holder, using the magnet and a screw to fix the pedestal  
659 to a custom-made restrainer, and the mouse was placed with the head in the center on a turntable  
660 (diameter 60 cm) in the experimental setup. A drum (diameter 63 cm) surrounded the mouse  
661 during the experiment. The recording camera was calibrated by moving the camera left–right by  
662 20° peak to peak at different light levels. Compensatory eye movement performance was  
663 examined by recording the OKR, VOR, and VVOR using a sinusoidal rotation of the drum in light  
664 (OKR), rotation of the table in the dark (VOR), or rotation of the table (VVOR) in the light. These  
665 reflexes were evoked by rotating the table and/or drum at 0.1 to 1 Hz (20 to 8 cycles, each  
666 recorded twice) with a fixed 5° amplitude. In order to evaluate motor learning, a mismatch  
667 between visual and vestibular input was used to adapt the VOR. The ability to perform VOR phase  
668 reversal was tested using a 5-day paradigm, consisting of six 5-minute training sessions every day  
669 with VOR recordings before, between, and after the training sessions. On the first day during  
670 training, the visual and vestibular stimuli rotated in phase at 0.6 Hz and at the same amplitude,

671 inducing a decrease of gain. On the subsequent days, the drum amplitude was increased relative to  
672 the table and induced the phase reversal of the VOR, resulting in a compensatory eye movement  
673 in the same direction as the head rotation instead of the normal compensatory opposite direction  
674 (all days vestibular 5° rotation, visual day 2: 5°; day 3, 7.5°; days 4–5, 10°). Between recording  
675 sessions, mice were kept in the dark to avoid unlearning of the adapted responses.

676 Eye movements were recorded with a video-based eye-tracking system (hard- and software,  
677 ETL-200; ISCAN systems, Burlington, MA). Recordings were always taken from the left eye. The  
678 eye was illuminated during the experiments using two table-fixed infrared emitters (output 600  
679 mW, dispersion angle 7°, peak wavelength 880 nm) and a third emitter that was mounted to the  
680 camera, aligned horizontally with the optical axis of the camera, which produced the tracked  
681 corneal reflection. Pupil size and corrected (with corneal reflection) vertical and horizontal pupil  
682 positions were determined by the ISCAN system, filtered (CyberAmp; Molecular Devices, San  
683 Jose, CA), digitized (CED, Cambridge, UK) and stored for offline analysis. All eye movement  
684 signals were calibrated, differentiated to obtain velocity signals, and high-pass-filtered to  
685 eliminate fast phases, and then cycles were averaged. Gain—the ratio of eye movement amplitude  
686 to stimulus amplitude—and phase values—time difference between eye and stimulus expressed in  
687 degrees—of eye movements were calculated using custom-made MATLAB routines (The  
688 MathWorks, Natick, MA).

689

### 690 **Statistical analysis**

691 Experimenters who performed experiments and analyses were blinded to the genotypes until all  
692 data were integrated. Data were analyzed using Igor Pro 6.0 (Wavemetrics, Lake Oswego, OR),

693 Graphpad Prism (San Diego, CA), SPSS 16.0 (IBM, Chicago, IL), and MATLAB. No statistical  
694 methods were used to pre-determine sample sizes, which were based on our previous studies. All  
695 data sets were tested for the assumptions of normality of distribution. No data were excluded  
696 except electrophysiological recordings with  $\geq 15\%$  variance in series resistance, input resistance,  
697 or holding current. Standard deviations for control were calculated from the average of all control  
698 data. Statistical differences were determined using unpaired two-sided Student's *t* test for  
699 two-group comparison, or one-way ANOVA followed by Tukey's post hoc post hoc test for  
700 multiple comparisons, or repeated measures ANOVA for repeated measures. The accepted level of  
701 significance was  $p < 0.05$ . "*n*" represents the number of preparations or cells. Data in the text and  
702 figures are presented as mean  $\pm$  SEM.

703 **References**

- 704 **Acuna C**, Liu X, Südhof TC. 2016. How to make an active zone: unexpected universal functional  
705 redundancy between RIMs and RIM-BPs. *Neuron* **91**:792–807. DOI:  
706 10.1016/j.neuron.2016.07.042, PMID: 27537484.
- 707 **Andreescu CE**, Prestori F, Brandalise F, D'Errico A, De Jeu MT, Rossi P, Botta L, Kohr G, Perin P,  
708 D'Angelo E, et al. 2011. NR2A subunit of the N-methyl D-aspartate receptors are required for  
709 potentiation at the mossy fiber to granule cell synapse and vestibulo-cerebellar motor  
710 learning. *Neuroscience* **176**:274–283. DOI: 10.1016/j.neuroscience.2010.12.024, PMID:  
711 21185357
- 712 **Badura A**, Clopath C, Schonewille M, De Zeeuw CI. 2016. Modeled changes of cerebellar  
713 activity in mutant mice are predictive of their learning impairments. *Scientific Reports*  
714 **6**:36131. DOI: 10.1038/srep36131, PMID: 27805050.
- 715 **Betz A**, Thakur P, Junge HJ, Ashery U, Rhee JS, Scheuss V, Rosenmund C, Rettig J, Brose N.  
716 2001. Functional interaction of the active zone proteins Munc13-1 and RIM1 in synaptic  
717 vesicle priming. *Neuron* **30**:183–196. DOI: 10.1016/s0896-6273(01)00272-0, PMID:  
718 11343654.
- 719 **Brushia RJ**, Walsh DA. 1999. Phosphorylase kinase: the complexity of its regulation is reflected  
720 in the complexity of its structure. *Frontiers in Bioscience* **4**:D618–641. DOI: 10.2741/brushia,  
721 PMID: 10487978.
- 722 **Cheng X**, Ji Z, Tsalkova T, Mei F. 2008. Epac and PKA: a tale of two intracellular cAMP  
723 receptors. *Acta Biochim Biophys Sin* **40**:651–662. DOI: 10.1111/j.1745-7270.2008.00438.x,  
724 PMID: 18604457.



- 725 **Davies MS**, Cox JW, Berners-Price SJ, Barklage W, Qu Y, Farrell N. 2000. Equilibrium and  
726 kinetic studies of the aquation of the dinuclear platinum complex  
727 [[trans-PtCl(NH<sub>3</sub>)<sub>2</sub>]<sub>2</sub>(μ-NH<sub>2</sub>(CH<sub>2</sub>)<sub>6</sub>NH<sub>2</sub>)]<sub>2</sub><sup>+</sup>: pK<sub>a</sub> determinations of aqua ligands via  
728 [<sup>1</sup>H,<sup>15</sup>N] NMR spectroscopy. *Inorganic Chemistry* **39**:1710–1715. DOI: 10.1021/ic991104h,  
729 PMID: 12526558.
- 730 **de Rooij J**, Zwartkruis FJ, Verheijen MH, Cool RH, Nijman SM, Wittinghofer A, Bos JL. 1998.  
731 Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. *Nature*  
732 **396**:474–477. DOI: 10.1038/24884, PMID: 9853756.
- 733 **De Zeeuw CI**. 2021. Bidirectional learning in upbound and downbound microzones of the  
734 cerebellum. *Nature Reviews Neuroscience* **22**, 92–110. DOI: 10.1038/s41583-020-00392-x,  
735 PMID: 33203932.
- 736 **Dulubova I**, Lou X, Lu J, Huryeva I, Alam A, Schneggenburger R, Südhof TC, Rizo J. 2005. A  
737 Munc13/RIM/Rab3 tripartite complex: from priming to plasticity? *EMBO Journal*  
738 **24**:2839–2850. DOI: 10.1038/sj.emboj.7600753, PMID: 16052212.
- 739 **Fernandes HB**, Riordan S, Nomura T, Remmers CL, Kraniotis S, Marshall JJ, Kukreja L, Vassar  
740 R, Contractor A. 2015. Epac2 mediates cAMP-dependent potentiation of neurotransmission  
741 in the hippocampus. *Journal of Neuroscience* **35**:6544–6553. DOI:  
742 10.1523/JNEUROSCI.0314-14.2015, PMID: 25904804.
- 743 **Ferrero JJ**, Alvarez AM, Ramírez-Franco J, Godino MC, Bartolomé-Martín D, Aguado C, Torres  
744 M, Luján R, Ciruela F, Sánchez-Prieto J. 2013. β-Adrenergic receptors activate exchange  
745 protein directly activated by cAMP (Epac), translocate Munc13-1, and enhance the  
746 Rab3A-RIM1α interaction to potentiate glutamate release at cerebrocortical nerve terminals.

747 *Journal of Biological Chemistry* **288**:31370–31385. DOI: 10.1074/jbc.M113.463877, PMID:

748 24036110.

749 **Galliano E**, Gao Z, Schonewille M, Todorov B, Simons E, Pop AS, D'Angelo E, van den

750 Maagdenberg AM, Hoebeek FE, De Zeeuw CI. 2013. Silencing the majority of cerebellar

751 granule cells uncovers their essential role in motor learning and consolidation. *Cell Reports*

752 **3**:1239–1251. DOI: 10.1016/j.celrep.2013.03.023, PMID: 23583179.

753 **Gao Z**, van Beugen BJ, De Zeeuw CI. 2012. Distributed synergistic plasticity and cerebellar

754 learning. *Nature Reviews Neuroscience* **13**:619–635. DOI: 10.1038/nrn3312, PMID:

755 22895474.

756 **Gekel I**, Neher E. 2008. Application of an Epac activator enhances neurotransmitter release at

757 excitatory central synapses. *Journal of Neuroscience* **28**:7991–8002. DOI:

758 10.1523/JNEUROSCI.0268-08.2008, PMID: 18685024.

759 **Grasselli G**, Boele HJ, Titley HK, Bradford N, van Beers L, Jay L, Beekhof GC, Busch SE, De

760 Zeeuw CI, Schonewille M, et al. 2020. SK2 channels in cerebellar Purkinje cells contribute

761 to excitability modulation in motor-learning-specific memory traces. *PLoS Biology*

762 **18**:e3000596. DOI: 10.1371/journal.pbio.3000596, PMID: 31905212.

763 **Gutierrez-Castellanos N**, Da Silva-Matos CM, Zhou K, Canto CB, Renner MC, Koene LMC,

764 Ozyildirim O, Sprengel R, Kessels HW, De Zeeuw CI. 2017. Motor learning requires

765 Purkinje cell synaptic potentiation through activation of AMPA-receptor subunit GluA3.

766 *Neuron* **93**:409–424. DOI: 10.1016/j.neuron.2016.11.046, PMID: 28103481.

767 **Han Y**, Kaeser PS, Südhof TC, Schneggenburger R. 2011. RIM determines Ca<sup>2+</sup> channel density

768 and vesicle docking at the presynaptic active zone. *Neuron* **69**:304–316. DOI:

- 769 10.1016/j.neuron.2010.12.014, PMID: 21262468.
- 770 **He Y**, Wei M, Wu Y, Qin H, Li W, Ma X, Cheng J, Ren J, Shen Y, Chen Z, et al. 2019. Amyloid  $\beta$   
771 oligomers suppress excitatory transmitter release via presynaptic depletion of  
772 phosphatidylinositol-4,5-bisphosphate. *Nature Communication* **10**:1193. DOI:  
773 10.1038/s41467-019-09114-z, PMID: 30867420.
- 774 **Hioki H**, Fujiyama F, Taki K, Tomioka R, Furuta T, Tamamaki N, Kaneko T. 2003. Differential  
775 distribution of vesicular glutamate transporters in the rat cerebellar cortex. *Neuroscience*  
776 **117**:1–6. DOI: 10.1016/s0306-4522(02)00943-0, PMID: 12605886.
- 777 **Hirano T**, Yamazaki Y, Nakamura Y. 2016. LTD, RP, and motor learning. *Cerebellum* **15**:51–53.  
778 DOI: 10.1007/s12311-015-0698-0, PMID: 26160222.
- 779 **Hucho TB**, Dina OA, Levine JD. 2005. Epac mediates a cAMP-to-PKC signaling in  
780 inflammatory pain: an isolectin B4(+) neuron-specific mechanism. *Journal of Neuroscience*  
781 **25**:6119–6126. DOI: 10.1523/JNEUROSCI.0285-05.2005, PMID: 15987941.
- 782 **Ichikawa R**, Hashimoto K, Miyazaki T, Uchigashima M, Yamasaki M, Aiba A, Kano M,  
783 Watanabe M. 2016. Territories of heterologous inputs onto Purkinje cell dendrites are  
784 segregated by mGluR1-dependent parallel fiber synapse elimination. *Proc. Natl. Acad. Sci.*  
785 *U.S.A.* **113**:2282–2287. DOI: 10.1073/pnas.1511513113, PMID: 26858447.
- 786 **Ito M**. 2005. Bases and implications of learning in the cerebellum-adaptive control and internal  
787 model mechanism. *Progress in Brain Research* **148**:95–109. DOI:  
788 10.1016/S0079-6123(04)48009-1, PMID: 15661184.
- 789 **Kaesler PS**, Deng L, Wang Y, Dulubova I, Liu X, Rizo J, Südhof TC. 2011. RIM proteins tether  
790  $\text{Ca}^{2+}$  channels to presynaptic active zones via a direct PDZ-domain interaction. *Cell*

- 791           **144**:282–295. DOI: 10.1016/j.cell.2010.12.029, PMID: 21241895.
- 792   **Kaeser PS**, Kwon HB, Blundell J, Chevaleyre V, Morishita W, Malenka RC, Powell CM, Castillo  
793           PE, Südhof TC. 2008. RIM1alpha phosphorylation at serine-413 by protein kinase A is not  
794           required for presynaptic long-term plasticity or learning. *Proc. Natl. Acad. Sci. U.S.A.*  
795           **105**:14680–14685. DOI: 10.1073/pnas.0806679105, PMID: 18799741.
- 796   **Kaneko M**, Takahashi T. 2004. Presynaptic mechanism underlying cAMP-dependent synaptic  
797           potentiation. *Journal of Neuroscience* **24**:5202–5208. DOI:  
798           10.1523/JNEUROSCI.0999-04.2004, PMID: 15175390.
- 799   **Kawasaki H**, Springett GM, Mochizuki N, Toki S, Nakaya M, Matsuda M, Housman DE,  
800           Graybiel AM. 1998. A family of cAMP-binding proteins that directly activate Rap1. *Science*  
801           **282**:2275–2279. DOI: 10.1126/science.282.5397.2275, PMID: 9856955.
- 802   **Kimura S**, Uchiyama S, Takahashi HE, Shibuki K. 1998. cAMP-dependent long-term  
803           potentiation of nitric oxide release from cerebellar parallel fibers in rats. *Journal of*  
804           *Neuroscience* **18**:8551–8558. DOI: 10.1523/JNEUROSCI.18-21-08551.1998, PMID:  
805           9786963.
- 806   **Kohansal-Nodehi M**, Chua JJ, Urlaub H, Jahn R, Czernik D. 2016. Analysis of protein  
807           phosphorylation in nerve terminal reveals extensive changes in active zone proteins upon  
808           exocytosis. *Elife* **5**:e14530. DOI: 10.7554/eLife.14530, PMID: 27115346.
- 809   **Kreitzer AC**, Carter AG, Regehr WG. 2002. Inhibition of interneuron firing extends the spread of  
810           endocannabinoid signaling in the cerebellum. *Neuron* **34**:787–796. DOI:  
811           10.1016/s0896-6273(02)00695-5, PMID: 12062024.
- 812   **Le Guen M-C**, De Zeeuw CI. 2010. Presynaptic plasticity at cerebellar parallel fiber terminals.

- 813 *Functional Neurology* **25**:141–151. PMID: 21232210.
- 814 **Lev-Ram V**, Wong ST, Storm DR, Tsien RY. 2002. A new form of cerebellar long-term  
815 potentiation is postsynaptic and depends on nitric oxide but not cAMP. *Proc. Natl. Acad. Sci.*  
816 *U.S.A.* **99**:8389–8393. DOI: 10.1073/pnas.122206399, PMID: 12048250.
- 817 **Linden DJ**, Ahn S. 1999. Activation of presynaptic cAMP-dependent protein kinase is required  
818 for induction of cerebellar long-term potentiation. *Journal of Neuroscience* **19**:10221–10227.  
819 DOI: 10.1523/JNEUROSCI.19-23-10221.1999, PMID: 10575019.
- 820 **Lonart G**, Schoch S, Kaeser PS, Larkin CJ, Südhof TC, Linden DJ. 2003. Phosphorylation of  
821 RIM1alpha by PKA triggers presynaptic long-term potentiation at cerebellar parallel fiber  
822 synapses. *Cell* **115**:49–60. DOI: 10.1016/s0092-8674(03)00727-x, PMID: 14532002.
- 823 **Lucchesi O**, Ruete MC, Bustos MA, Quevedo MF, Tomes CN. 2016. The signaling module  
824 cAMP/Epac/Rap1/PLCε/IP3 mobilizes acrosomal calcium during sperm exocytosis.  
825 *Biochimica Biophysica Acta* **1863**:544–561. DOI: 10.1016/j.bbamcr.2015.12.007, PMID:  
826 26704387.
- 827 **Martín R**, Garcia-Font N, Suarez-Pinilla AS, Bartolome-Martin D, Ferrero JJ, Lujan R, Torres M,  
828 Sanchez-Prieto J. 2020. beta-adrenergic receptors/Epac signaling increases the size of the  
829 readily releasable pool of synaptic vesicles required for parallel fiber LTP. *Journal of*  
830 *Neuroscience* **40**:8604–8617. DOI: 10.1523/JNEUROSCI.0716-20.2020, PMID: 33046543.
- 831 **Mei FC**, Qiao J, Tsygankova OM, Meinkoth JL, Quilliam LA, Cheng X. 2002. Differential  
832 signaling of cyclic AMP: opposing effects of exchange protein directly activated by cyclic  
833 AMP and cAMP-dependent protein kinase on protein kinase B activation. *Journal of*  
834 *Biological Chemistry* **277**:11497–11504. DOI: 10.1074/jbc.M110856200, PMID: 11801596.

- 835 **Murray AJ**. 2008. Pharmacological PKA inhibition: all may not be what it seems. *Science*  
836 *Signaling* **1**:re4. DOI: 10.1126/scisignal.122re4, PMID: 18523239.
- 837 **Oestreich EA**, Malik S, Goonasekera SA, Blaxall BC, Kelley GG, Dirksen RT, Smrcka AV. 2009.  
838 Epac and phospholipase Cepsilon regulate Ca<sup>2+</sup> release in the heart by activation of protein  
839 kinase Cepsilon and calcium-calmodulin kinase II. *Journal of Biological Chemistry*  
840 **284**:1514–1522. DOI: 10.1074/jbc.M806994200, PMID: 18957419.
- 841 **Persoon CM**, Hoogstraaten RI, Nassal JP, van Weering JRT, Kaeser PS, Toonen RF, Verhage M.  
842 2019. The RAB3-RIM pathway is essential for the release of neuromodulators. *Neuron*  
843 **104**:1065–1080. DOI: 10.1016/j.neuron.2019.09.015, PMID: 31679900.
- 844 **Peter S**, Ten Brinke MM, Stedehouder J, Reinelt CM, Wu B, Zhou H, Zhou K, Boele HJ, Kushner  
845 SA, Lee MG, et al. 2016. Dysfunctional cerebellar Purkinje cells contribute to autism-like  
846 behaviour in Shank2-deficient mice. *Nature Communication* **7**:12627. DOI:  
847 10.1038/ncomms12627, PMID: 27581745.
- 848 **Raymond JL**, Medina JF. 2018. Computational principles of supervised learning in the  
849 cerebellum. *Annual Review of Neuroscience* **41**:233–253. DOI:  
850 10.1146/annurev-neuro-080317-061948, PMID: 29986160.
- 851 **Roscioni SS**, Kistemaker LEM, Menzen MH, Elzinga CRS, Gosens R, Halayko AJ, Meurs H,  
852 Schmidt, M. 2009. PKA and Epac cooperate to augment bradykinin-induced interleukin-8  
853 release from human airway smooth muscle cells. *Respiratory Research* **10**:88. DOI:  
854 10.1186/1465-9921-10-88, PMID: 19788733.
- 855 **Salin PA**, Malenka RC, Nicoll RA. 1996. Cyclic AMP mediates a presynaptic form of LTP at  
856 cerebellar parallel fiber synapses. *Neuron* **16**:797–803. DOI:

- 857 10.1016/s0896-6273(00)80099-9, PMID: 8607997.
- 858 **Schmahmann JD**, Guell X, Stoodley CJ, Halko MA. 2019. The theory and neuroscience of  
859 cerebellar cognition. *Annual Review of Neuroscience* **42**:337–364. DOI:  
860 10.1146/annurev-neuro-070918-050258, PMID: 30939101.
- 861 **Schmidt M**, Evellin S, Weernink PA, von Dorp F, Rehmann H, Lomasney JW, Jakobs KH. 2001.  
862 A new phospholipase-C-calcium signalling pathway mediated by cyclic AMP and a Rap  
863 GTPase. *Nature Cell Biology* **3**:1020–1024. DOI: 10.1038/ncb1101-1020, PMID: 11715024.
- 864 **Schoch S**, Castillo PE, Jo T, Mukherjee K, Geppert M, Wang Y, Schmitz F, Malenka RC, Südhof  
865 TC. 2002. RIM1alpha forms a protein scaffold for regulating neurotransmitter release at the  
866 active zone. *Nature* **415**:321–326. DOI: 10.1038/415321a, PMID: 11797009.
- 867 **Schonewille M**, Belmeguenai A, Koekkoek SK, Houtman SH, Boele HJ, van Beugen BJ, Gao Z,  
868 Badura A, Ohtsuki G, Amerika WE, et al. 2010. Purkinje cell-specific knockout of the protein  
869 phosphatase PP2B impairs potentiation and cerebellar motor learning. *Neuron* **67**:618–628.  
870 DOI: 10.1016/j.neuron.2010.07.009, PMID: 20797538.
- 871 **Schonewille M**, Girasole AE, Rostaing P, Mailhes-Hamon C, Ayon A, Nelson AB, Triller A,  
872 Casado M, De Zeeuw CI, Bouvier G. 2021. NMDARs in granule cells contribute to parallel  
873 fiber-Purkinje cell synaptic plasticity and motor learning. *Proc. Natl. Acad. Sci. U.S.A.*  
874 **118**:e2102635118. DOI: 10.1073/pnas.2102635118, PMID: 34507990.
- 875 **Steinberg JP**, Takamiya K, Shen Y, Xia J, Rubio ME, Yu S, Jin W, Thomas GM, Linden DJ,  
876 Huganir RL. 2006. Targeted in vivo mutations of the AMPA receptor subunit GluR2 and its  
877 interacting protein PICK1 eliminate cerebellar long-term depression. *Neuron* **49**:845–860.  
878 DOI: 10.1016/j.neuron.2006.02.025, PMID: 16543133.

879 **Südhof TC**. 2004. The synaptic vesicle cycle. *Annual Review of Neuroscience* **27**:509–547. DOI:

880 10.1146/annurev.neuro.26.041002.131412, PMID: 15217342.

881 **Sun L**, Bittner MA, Holz RW. 2003. Rim, a component of the presynaptic active zone and

882 modulator of exocytosis, binds 14-3-3 through its N terminus. *Journal of Biological*

883 *Chemistry* **278**:38301–38309. DOI: 10.1074/jbc.M212801200, PMID: 12871946.

884 **ten Brinke MM**, Boele HJ, Spanke JK, Potters JW, Kornysheva K, Wulff P, IJpelaar AC,

885 Koekkoek SK, De Zeeuw CI. 2015. Evolving models of Pavlovian conditioning: cerebellar

886 cortical dynamics in awake behaving mice. *Cell Reports* **13**:1977–1988. DOI:

887 10.1016/j.celrep.2015.10.057, PMID: 26655909.

888 **van Beugen BJ**, Gao Z, Boele HJ, Hoebeek F, De Zeeuw CI. 2013. High frequency burst firing of

889 granule cells ensures transmission at the parallel fiber to purkinje cell synapse at the cost of

890 temporal coding. *Frontiers in Neural Circuits* **7**:95. DOI: 10.3389/fncir.2013.00095, PMID:

891 23734102.

892 **Voges K**, Wu B, Post L, Schonewille M, De Zeeuw CI. 2017. Mechanisms underlying

893 vestibulo-cerebellar motor learning in mice depend on movement direction. *Journal of*

894 *Physiology* **595**:5301–5326. DOI: 10.1113/JP274346, PMID: 28586131.

895 **Wagner MJ**, Luo L. 2020. Neocortex-cerebellum circuits for cognitive processing. *Trends in*

896 *Neuroscience* **43**, 42–54. DOI: 10.1016/j.tins.2019.11.002, PMID: 31787351.

897 **Wang CC**, Weyrer C, Fioravante D, Kaeser PS, Regehr WG. 2021a. Presynaptic short-term

898 plasticity persists in the absence of PKC phosphorylation of Munc18-1. *Journal of*

899 *Neuroscience* **41**:7329–7339. DOI: 10.1523/JNEUROSCI.0347-21.2021, PMID: 34290081.

900 **Wang DJ**, Su LD, Wang YN, Yang D, Sun CL, Zhou L, Wang XX, Shen Y. 2014. Long-term



901           potentiation at cerebellar parallel fiber-Purkinje cell synapses requires pre- and postsynaptic  
902           signaling cascades. *Journal of Neuroscience* **34**:2355–2364. DOI: 10.1152/jn.00175.2018,  
903           PMID: 29668384.

904   **Wang X**, Hu B, Zimmermann B, Kilimann MW. 2001. Rim1 and rabphilin-3 bind Rab3-GTP by  
905           composite determinants partially related through N-terminal alpha-helix motifs. *Journal of*  
906           *Biological Chemistry* **276**:32480–32488. DOI: 10.1074/jbc.M103337200, PMID: 11431472.

907   **Wang XT**, Zhou L, Cai XY, Xu FX, Xu ZH, Li XY, Shen Y. 2021b. Deletion of Mea6 in  
908           cerebellar granule cells impairs synaptic development and motor performance. *Frontiers in*  
909           *Cell & Development Biology* **8**:627146. DOI: 10.3389/fcell.2020.627146, PMID: 33718348.

910   **Weisskopf MG**, Castillo PE, Zalutsky RA, Nicoll RA. 1994. Mediation of hippocampal mossy  
911           fiber long-term potentiation by cyclic AMP. *Science* **265**:1878–1882. DOI:  
912           10.1126/science.7916482, PMID: 7916482.

913   **Wu B**, Blot FG, Wong AB, Osório C, Adolfs Y, Pasterkamp RJ, Hartmann J, Becker EB, Boele H  
914           J, De Zeeuw CI, Schonwille M. 2019. TRPC3 is a major contributor to functional  
915           heterogeneity of cerebellar Purkinje cells. *eLife* **8**:e45590. DOI: 10.7554/eLife.45590, PMID:  
916           31486767.

917   **Wulff P**, Schonwille M, Renzi M, Viltono L, Sassoè-Pognetto M, Badura A, Gao Z, Hoebeek FE,  
918           van Dorp S, Wisden W, et al. 2009. Synaptic inhibition of Purkinje cells mediates  
919           consolidation of vestibulo-cerebellar motor learning. *Nature Neuroscience* **12**:1042–1049.  
920           DOI: 10.1038/nn.2348, PMID: 19578381.

921   **Yang Y**, Calakos N. 2010. Acute in vivo genetic rescue demonstrates that phosphorylation of  
922           RIM1alpha serine 413 is not required for mossy fiber long-term potentiation. *Journal of*  
923           *Neuroscience* **30**:2542–2546. DOI: 10.1523/JNEUROSCI.4285-09.2010, PMID: 20164339.

- 924 **Yang Y**, Shu X, Liu D, Shang Y, Wu Y, Pei L, Xu X, Tian Q, Zhang J, Qian K, et al. 2012. EPAC  
925 null mutation impairs learning and social interactions via aberrant regulation of miR-124 and  
926 Zif268 translation. *Neuron* **73**:774–788. DOI: 10.1016/j.neuron.2012.02.003, PMID:  
927 22365550.
- 928 **Zhao K**, Wen R, Wang X, Pei L, Yang Y, Shang Y, Bazan N, Zhu LQ, Tian Q, Lu Y. 2013.  
929 EPAC inhibition of SUR1 receptor increases glutamate release and seizure vulnerability.  
930 *Journal of Neuroscience* **33**:8861–8865. DOI: 10.1523/JNEUROSCI.5686-12.2013, PMID:  
931 23678128.
- 932 **Zhou JH**, Wang XT, Zhou L, Zhou L, Xu FX, Su LD, Wang H, Jia F, Xu FQ, Chen GQ, et al.  
933 2017. Ablation of TFR1 in Purkinje cells inhibits mGlu1 trafficking and impairs motor  
934 coordination, but not autistic-like behaviors. *Journal of Neuroscience* **37**:11335–11352. DOI:  
935 10.1523/JNEUROSCI.1223-17.2017, PMID: 29054881.
- 936 **Zhou L**, Yang D, Wang DJ, Xie YJ, Zhou JH, Zhou L, Huang H, Han S, Shao CY, Li HS, et al.  
937 2015. Numb deficiency in cerebellar Purkinje cells impairs synaptic expression of  
938 metabotropic glutamate receptor and motor coordination. *Proc. Natl. Acad. Sci. U.S.A.*  
939 **112**:15474–15479. DOI: 10.1073/pnas.1512915112, PMID: 26621723.

940 **Acknowledgements**

941 We thank Drs. Jia-Dong Chen and Yan Gu for their comments on this work, Drs. You-Min Lu and  
942 Wei Mo for providing *Epac*<sup>dKO</sup> and *Math1*-Cre mice, Dr. Lan Bao for providing assistance in  
943 electron microscopy, Drs. Min Wu and Jun Xia for their participation at the beginning of this work,  
944 and the Core Facilities of Zhejiang University Institute of Neuroscience for technical assistance.  
945 This work was supported by grants from National Natural Science Foundation of China  
946 (81625006 to Y.S., 31820103005 to Y.S., 32000692 to X.T.W., 32160192 to Y.W., 32100791 to  
947 F.X.X., 31900741 to L.Z., 32170976 to L.Z.), National Key Research and Development Program  
948 of the Ministry of Science and Technology of China (2020YFB1313500 to L.Z.), Science and  
949 Technology Innovation Commission of Shenzhen Municipal Government  
950 (JCYJ20160331115633182 to S.J.J.), Ningxia Key Research and Development Program  
951 (2021BEG03097 to Y.W.), ERC-Stg (680235 to M.S.), the Dutch Organization for Medical  
952 Sciences (C.I.D.Z.), Life Sciences (C.I.D.Z.), and ERC-adv and ERC-POC of the EU (C.I.D.Z.),  
953 INTENSE (C.I.D.Z.), and the NIN Vriendenfonds for albinism (C.I.D.Z.).

954

955 **Ethics**

956 All of the animals were handled according to approved protocol of the Animal Experimentation  
957 Ethics Committee of Zhejiang University (ZJU17067).

958 **Figure legends**

959

960 **Figure 1.** Threonine phosphorylation of RIM1 by EPAC and PKC $\epsilon$ . (A) Schematic showing  
961 purification of cerebellar synaptosomes and phosphorylation assay of RIM1. (B) Immunostaining  
962 of EPAC1 or EPAC2 along with vGluT1 (arrowheads) in cerebellar synaptosomes. Scale bars, 5  
963  $\mu$ m. (C) Precleared synaptosomes (WT) were immunoprecipitated with anti-RIM1 antibody and  
964 probed with antibodies to EPAC1, EPAC2 and RIM1. Rabbit IgG was negative control.  $n = 4$ . (D)  
965 WT synaptosomes were treated with control buffer (Ctrl) or 8-pCPT (20  $\mu$ M, 30 min) and p-Thr  
966 and p-Ser of RIM1 were analyzed. Arrowheads mark non-RIM1 proteins. p-Thr and p-Ser were  
967 normalized to corresponding RIM1 and percentage changes relative to Ctrl are plotted. p-Thr: 100  
968  $\pm$  8% (Ctrl) and 179  $\pm$  18% (8-pCPT;  $p = 0.0019$ ). p-Ser: 100  $\pm$  6% (Ctrl) and 97  $\pm$  11% (8-pCPT;  
969  $p = 0.77$ ). Unpaired  $t$  test.  $n = 5$  for all groups.  $**p < 0.01$ . (E) p-Thr and p-Ser of RIM1 in WT  
970 synaptosomes treated with control buffer, forskolin (FSK; 20  $\mu$ M, 30 min), or FSK+ESI-09 (50  
971  $\mu$ M, 30 min) (FSK+ESI). Arrowhead marks nonspecific protein. p-Thr: 100  $\pm$  8% (Ctrl), 205  $\pm$  18%  
972 (FSK;  $p < 0.001$  vs. Ctrl), and 101  $\pm$  14% (FSK+ESI;  $p = 0.98$  vs. Ctrl;  $p < 0.001$  vs. FSK).  
973 One-way ANOVA test.  $n = 5$  for all groups.  $***p < 0.001$ . (F) Phosphorylation of synaptosomal  
974 RIM1 from WT and *Epac*<sup>dKO</sup> mice. RIM1: 100  $\pm$  4% (WT) and 95  $\pm$  4% (*Epac*<sup>dKO</sup>;  $p = 0.41$ ).  
975 p-Thr: 100  $\pm$  3% (WT) and 65  $\pm$  6% (*Epac*<sup>dKO</sup>;  $p = 0.0003$ ). p-Ser: 100  $\pm$  5% (WT) and 95  $\pm$  9%  
976 (*Epac*<sup>dKO</sup>;  $p = 0.67$ ). Unpaired  $t$  test.  $n = 6$  for all groups.  $***p < 0.001$ . (G) Schematic depiction  
977 of proposed working model. (H) Immunostaining of PKC $\epsilon$  and vGluT1 (arrowheads) in cerebellar  
978 synaptosomes. Scale bar, 5  $\mu$ m. (I) WT synaptosomes were treated with control buffer or 8-pCPT  
979 (20  $\mu$ M, 30 min). The phosphorylations of PKC $\epsilon$  and PKC $\alpha$  were normalized to  $\beta$ -tubulin and

980 percentage changes relative to control are plotted. pPKC $\epsilon$ :  $100 \pm 5\%$  (Ctrl) and  $142 \pm 7\%$  (8-pCPT;  
981  $p = 0.0007$ ). PKC $\alpha$ -pSer:  $100 \pm 8\%$  (Ctrl) and  $113 \pm 11\%$  (8-pCPT;  $p = 0.31$ ). PKC $\alpha$ -pThr:  $100 \pm$   
982  $7\%$  (Ctrl) and  $93 \pm 10\%$  (8-pCPT;  $p = 0.54$ ). Unpaired  $t$  test.  $n = 5$  for all groups. \*\*\* $p < 0.001$ . (J)  
983 Phosphorylation of synaptosomal PKC $\epsilon$  and PKC $\alpha$  in WT and *Epac*<sup>dKO</sup> mice. pPKC $\epsilon$ , PKC $\alpha$ -pSer  
984 and PKC $\alpha$ -pThr were normalized to  $\beta$ -tubulin and their percentage changes relative to WT are  
985 plotted. pPKC $\epsilon$ :  $100 \pm 5\%$  (WT) and  $64 \pm 7\%$  (*Epac*<sup>dKO</sup>;  $p = 0.0013$ ). PKC $\alpha$ -pSer:  $100 \pm 4\%$  (WT)  
986 and  $103 \pm 8\%$  (*Epac*<sup>dKO</sup>;  $p = 0.70$ ). PKC $\alpha$ -pThr:  $100 \pm 6\%$  (WT) and  $103 \pm 7\%$  (*Epac*<sup>dKO</sup>;  $p =$   
987  $0.73$ ). Unpaired  $t$  test.  $n = 6$  for all groups. \*\* $p < 0.01$ . (K) Phosphorylation of synaptosomal  
988 RIM1 in *Prkce*<sup>ff</sup> and *Prkce*<sup>cKO</sup> mice. RIM1:  $100 \pm 6\%$  (WT) and  $99 \pm 6\%$  (*Epac*<sup>dKO</sup>;  $p = 0.88$ ).  
989 p-Thr:  $100 \pm 3\%$  (*Prkce*<sup>ff</sup>) and  $65 \pm 6\%$  (*Prkce*<sup>cKO</sup>;  $p = 0.0028$ ). p-Ser:  $100 \pm 5\%$  (*Prkce*<sup>ff</sup>) and  $95$   
990  $\pm 9\%$  (*Prkce*<sup>cKO</sup>;  $p = 0.57$ ). Unpaired  $t$  test.  $n = 6$  for all groups. \*\* $p < 0.01$ . (L) Synaptosomes  
991 (*Prkce*<sup>cKO</sup>) were treated wi/wo 8-pCPT (20  $\mu$ M, 30 min) and RIM1 phosphorylation was analyzed.  
992 p-Thr:  $100 \pm 8\%$  (*Prkce*<sup>cKO</sup>) and  $108 \pm 10\%$  (*Prkce*<sup>cKO</sup>+8-pCPT;  $p = 0.55$ ). p-Ser:  $100 \pm 7\%$   
993 (*Prkce*<sup>cKO</sup>) and  $106 \pm 6\%$  (*Prkce*<sup>cKO</sup>+8-pCPT;  $p = 0.57$ ). Unpaired  $t$  test.  $n = 6$  for all groups.

994 **Figure 2.** EPAC and PKC $\epsilon$  act on vesicle docking, synaptic release, and Rab3-RIM1-Munc13  
995 complex. (A) Representative EM (23,000 $\times$ ) of PF-PC synapses of WT and *Epac*<sup>dkO</sup> mice. Scale  
996 bars: 200 nm. The inserts show docked vesicles. Unpaired *t* test. \*\*\*\**p* < 0.0001. (B)  
997 Representative EM of PF-PC synapses of *Prkce*<sup>ff</sup> and *Prkce*<sup>ckO</sup> mice. Scale bars: 200 nm.  
998 Unpaired *t* test. \*\*\*\**p* < 0.0001. (C) Example PC mEPSCs in *Math1*-Cre and *Epac1*<sup>ckO</sup>;*Epac2*<sup>ckO</sup>  
999 mice. Lower: statistics of inter-event interval and amplitude. Grey dots indicate individual data  
1000 points. Frequency: 2.0  $\pm$  0.2 Hz (*Math1*-Cre) and 1.4  $\pm$  0.2 Hz (*Epac1*<sup>ckO</sup>;*Epac2*<sup>ckO</sup>; *p* = 0.0036).  
1001 Amplitude: 18.3  $\pm$  1.3 pA (*Math1*-Cre) and 18.5  $\pm$  1.3 pA (*Epac1*<sup>ckO</sup>;*Epac2*<sup>ckO</sup>; *p* = 0.46).  
1002 Unpaired *t* test. *n* = for all groups. \*\**p* < 0.01. (D) Example PC mEPSCs from *Prkce*<sup>ff</sup> and  
1003 *Prkce*<sup>ckO</sup> mice. Frequency: 1.9  $\pm$  0.1 Hz (*Prkce*<sup>ff</sup>; *n* = 19) and 1.3  $\pm$  0.1 Hz (*Prkce*<sup>ckO</sup>; *n* = 20; *p* =  
1004 0.00059). Amplitude: 17.9  $\pm$  1.2 pA (*Prkce*<sup>ff</sup>; *n* = 19) and 17.5  $\pm$  1.1 pA (*Prkce*<sup>ckO</sup>; *n* = 20; *p* =  
1005 0.39). Unpaired *t* test. \*\*\**p* < 0.001. (E) Representative responses of *Math1*-Cre and  
1006 *Epac1*<sup>ckO</sup>;*Epac2*<sup>ckO</sup> PCs to 20-Hz PF stimulation. RRP size was defined as the y-intercept of the  
1007 linear portion of cumulative amplitude curve. For cumulative amplitude, *Math1*-Cre: 5617  $\pm$  358  
1008 pA; *Epac1*<sup>ckO</sup>;*Epac2*<sup>ckO</sup>: 4971  $\pm$  424 pA; *p* = 0.037, unpaired *t* test. Pr was calculated as mean  
1009 EPSC amplitude (mean value of 1st EPSCs) divided by RRP size (*Math1*-Cre: 0.068  $\pm$  0.015;  
1010 *Epac1*<sup>ckO</sup>;*Epac2*<sup>ckO</sup>: 0.044  $\pm$  0.010; *p* = 0.048, unpaired *t* test). *n* = 10 for all groups. \**p* < 0.05. (F)  
1011 Representative responses of *Prkce*<sup>ff</sup> and *Prkce*<sup>ckO</sup> PCs to 20-Hz PF stimulation. Cumulative  
1012 amplitude: *Prkce*<sup>ff</sup>, 5125  $\pm$  461 pA, *n* = 11; *Prkce*<sup>ckO</sup>, 3996  $\pm$  316 pA, *n* = 12; *p* = 0.041; Unpaired  
1013 *t* test. Pr: *Prkce*<sup>ff</sup>, 0.077  $\pm$  0.011, *n* = 11; *Prkce*<sup>ckO</sup>, 0.048  $\pm$  0.006, *n* = 12; *p* = 0.02; Unpaired *t* test.  
1014 \**p* < 0.05. (G) Cerebellar synaptosomes from WT and *Epac*<sup>dkO</sup> mice were immunoprecipitated by  
1015 anti-RIM1 antibody, and the immunoprecipitates were probed with antibodies to Munc13-1,

1016 Rab3A, and RIM1. Rabbit IgG was negative control. Ratios of immunoprecipitated Munc13-1 or  
1017 Rab3A vs. RIM1 were normalized to WT. Munc13-1:  $100 \pm 6\%$  (WT) and  $62 \pm 8\%$  (*Epac*<sup>dKO</sup>;  $p =$   
1018  $0.0081$ ,  $n = 4$ ). Rab3A:  $100 \pm 5\%$  (WT) and  $63 \pm 10\%$  (*Epac*<sup>dKO</sup>;  $p = 0.019$ ,  $n = 4$ ). Total Rab3A  
1019 and RIM1 were normalized to WT. Munc13-1:  $100 \pm 2\%$  (WT) and  $98 \pm 4\%$  (*Epac*<sup>dKO</sup>;  $p = 0.73$ ,  $n$   
1020  $= 6$ ). Rab3A:  $100 \pm 5\%$  (WT) and  $98 \pm 4\%$  (*Epac*<sup>dKO</sup>;  $p = 0.77$ ,  $n = 6$ ). Unpaired  $t$  test.  $*p < 0.05$ .  
1021  $**p < 0.01$ . (H) Immunoprecipitation of Munc13-1 and Rab3A with RIM1 in cerebellar  
1022 synaptosomes from *Prkce*<sup>ff</sup> and *Prkce*<sup>ckO</sup> mice. Ratios of immunoprecipitated Munc13-1 or  
1023 Rab3A vs. RIM1 were normalized to WT. Munc13-1:  $100 \pm 2\%$  (*Prkce*<sup>ff</sup>) and  $70 \pm 8\%$  (*Prkce*<sup>ckO</sup>;  
1024  $p = 0.0030$ ). Rab3A:  $100 \pm 2\%$  (*Prkce*<sup>ff</sup>) and  $89 \pm 4\%$  (*Prkce*<sup>ckO</sup>;  $p = 0.019$ ). Total Rab3A and  
1025 RIM1 were normalized to *Prkce*<sup>ff</sup>. Munc13-1:  $100 \pm 3\%$  (*Prkce*<sup>ff</sup>) and  $96 \pm 5\%$  (*Prkce*<sup>ckO</sup>;  $p =$   
1026  $0.46$ ). Rab3A:  $100 \pm 7\%$  (*Prkce*<sup>ff</sup>) and  $106 \pm 5\%$  (*Prkce*<sup>ckO</sup>;  $p = 0.52$ ).  $n = 6$  for all groups.  
1027 Unpaired  $t$  test.  $*p < 0.05$ .  $**p < 0.01$ . (I) Cerebellar synaptosomes (WT) mice were incubated in  
1028 control buffer or 8-pCPT (20  $\mu$ M, 30 min) and  $\epsilon$ V1-2 (5  $\mu$ M, 30min) and immunoprecipitated.  
1029 Ratios of immunoprecipitated Munc13-1 or Rab3A vs. RIM1 were normalized to control.  
1030 Munc13-1:  $100 \pm 8\%$  (Ctrl);  $138 \pm 12\%$  (8-pCPT;  $p = 0.041$  vs. Ctrl);  $96 \pm 12\%$  (8-pCPT+ $\epsilon$ V1-2;  
1031  $p = 0.97$  vs. Ctrl;  $p = 0.029$  vs. 8-pCPT). Rab3A:  $100 \pm 5\%$  (Ctrl);  $168 \pm 12\%$  (8-pCPT;  $p =$   
1032  $0.0011$  vs. Ctrl);  $133 \pm 12\%$  (8-pCPT+ $\epsilon$ V1-2;  $p = 0.069$  vs. Ctrl;  $p = 0.046$  vs. 8-pCPT). One-way  
1033 ANOVA test.  $n = 4$  for all groups.  $*p < 0.05$ .  $**p < 0.01$ . (J) Cerebellar synaptosomes (WT) were  
1034 treated with control buffer or FR236924 (FR) (200 nM, 30 min) and immunoprecipitated. Ratios  
1035 of immunoprecipitated Munc13-1 or Rab3A vs. RIM1 were normalized to Ctrl. Munc13-1:  $100 \pm$   
1036  $4\%$  (Ctrl) and  $144 \pm 16\%$  (FR;  $p = 0.041$ ). Rab3A:  $100 \pm 4\%$  (Ctrl) and  $175 \pm 13\%$  (FR;  $p =$   
1037  $0.0016$ ). Unpaired  $t$  test.  $n = 4$  for all groups.  $*p < 0.05$ .  $**p < 0.01$ . (K) Cerebellar synaptosomes

1038 (*Prkce*<sup>ckO</sup>) were treated with control buffer or FR236924 and immunoprecipitated. Ratios of  
1039 immunoprecipitated Munc13-1 or Rab3A vs. RIM1 were normalized to *Prkce*<sup>ckO</sup>. Munc13-1: 100  
1040  $\pm$  3% (*Prkce*<sup>ckO</sup>;  $n = 4$ ) and 100  $\pm$  12% (*Prkce*<sup>ckO</sup>+FR;  $p = 0.99$ ;  $n = 4$ ). Rab3A: 100  $\pm$  2%  
1041 (*Prkce*<sup>ckO</sup>;  $n = 8$ ) and 108  $\pm$  9% (*Prkce*<sup>ckO</sup>+FR;  $p = 0.37$ ;  $n = 8$ ). Unpaired *t* test.



1042 **Figure 3.** EPAC and PKC $\epsilon$  are required for presynaptic PF-PC LTP. (A) Schematic showing the  
1043 induction of presynaptic LTP. (B, D, F, H, J) Example PF-EPSCs for baseline (1) and after LTP  
1044 induction (2) in WT (B), *Math1*-Cre (D), *Epac1*<sup>ckO</sup>;*Epac2*<sup>ckO</sup> (F), *Prkce*<sup>ff</sup> (H), and *Prkce*<sup>ckO</sup> (J)  
1045 mice. (C) Percentage changes of PF-EPSC amplitudes (WT). (1): 101  $\pm$  4%; (2): 131  $\pm$  6%;  $n = 13$ ;  
1046  $p < 0.001$ . Percentage changes of PPF ratios from cells shown above. (1): 101  $\pm$  3%; (2): 84  $\pm$  4%;  
1047  $n = 13$ ;  $p < 0.001$ . Unpaired  $t$  test. \*\*\* $p < 0.001$ . (E) Left: percentage changes of PF-EPSC  
1048 amplitudes (*Math1*-Cre). (1): 100  $\pm$  2%; (2): 120  $\pm$  5%;  $n = 10$ ;  $p = 0.004$ . Right: percentage  
1049 changes of PPF ratios. (1): 102  $\pm$  2%; (2): 83  $\pm$  2%;  $n = 10$ ;  $p < 0.001$ . Unpaired  $t$  test. \*\* $p < 0.01$ .  
1050 \*\*\* $p < 0.001$ . (G) Left: percentage changes of PF-EPSC amplitudes (*Epac1*<sup>ckO</sup>;*Epac2*<sup>ckO</sup>). (1): 99  
1051  $\pm$  2%; (2): 93  $\pm$  4%;  $n = 9$ ;  $p = 0.059$ . Right: percentage changes of PPF ratios. (1): 101  $\pm$  3%; (2):  
1052 101  $\pm$  5%;  $n = 9$ ;  $p = 0.07$ . Unpaired  $t$  test. (I) Left: percentage changes of PF-EPSC amplitudes  
1053 (*Prkce*<sup>ff</sup>). (1): 99  $\pm$  4%; (2): 120  $\pm$  3%;  $n = 7$ ;  $p = 0.004$ . Right: percentage changes of PPF ratios.  
1054 (1): 100  $\pm$  5%; (2): 86  $\pm$  4%;  $n = 7$ ;  $p < 0.001$ . Unpaired  $t$  test. \*\* $p < 0.01$ . \*\*\* $p < 0.001$ . (K) Left:  
1055 percentage changes of PF-EPSC amplitudes (*Prkce*<sup>ckO</sup>). (1): 101  $\pm$  4%; (2): 99  $\pm$  5%;  $n = 10$ ;  $p =$   
1056 0.065. Right: percentage changes of PPF ratios. (1): 101  $\pm$  3%; (2): 100  $\pm$  2%;  $n = 10$ ;  $p = 0.77$ .  
1057 Unpaired  $t$  test.

1058 **Figure 4.** cAMP-triggered PF facilitation is dependent on EPAC and PKC $\epsilon$ . (A) The facilitation of  
1059 PF-EPSCs by forskolin (FSK) (20  $\mu$ M) in *Math1*-Cre, *Epac1*<sup>ckO</sup>;*Epac2*<sup>ckO</sup> and *Prkce*<sup>ckO</sup> mice. (B)  
1060 Example traces for baseline (1) and after potentiation (2) shown in (A). (C) Left: percent changes  
1061 of EPSC amplitude. *Math1*-Cre:  $366 \pm 25\%$  ( $n = 15$ ); *Epac1*<sup>ckO</sup>;*Epac2*<sup>ckO</sup>:  $162 \pm 18\%$  ( $n = 12$ ;  $p <$   
1062  $0.001$  vs. *Math1*-Cre); *Epac1*<sup>ckO</sup>;*Epac2*<sup>ckO</sup>+KT:  $106 \pm 4\%$  ( $n = 12$ ;  $p < 0.001$  vs. *Math1*-Cre;  $p =$   
1063  $0.046$  vs. *Epac1*<sup>ckO</sup>;*Epac2*<sup>ckO</sup>); *Prkce*<sup>ckO</sup>:  $198 \pm 5\%$  ( $n = 12$ ;  $p < 0.001$  vs. *Math1*-Cre);  
1064 *Prkce*<sup>ckO</sup>+KT:  $101 \pm 3\%$  ( $n = 12$ ;  $p < 0.001$  vs. *Math1*-Cre;  $p = 0.0034$  vs. *Prkce*<sup>ckO</sup>). Right:  
1065 percent changes of PPF. *Math1*-Cre:  $77 \pm 2\%$  ( $n = 15$ ); *Epac1*<sup>ckO</sup>;*Epac2*<sup>ckO</sup>:  $90 \pm 1\%$  ( $n = 12$ ;  $p <$   
1066  $0.001$  vs. *Math1*-Cre); *Epac1*<sup>ckO</sup>;*Epac2*<sup>ckO</sup>+KT:  $94 \pm 1\%$  ( $n = 12$ ;  $p < 0.001$  vs. *Math1*-Cre;  $p =$   
1067  $0.049$  vs. *Epac1*<sup>ckO</sup>;*Epac2*<sup>ckO</sup>); *Prkce*<sup>ckO</sup>:  $85 \pm 2\%$  ( $n = 12$ ;  $p < 0.001$  vs. *Math1*-Cre);  
1068 *Prkce*<sup>ckO</sup>+KT:  $95 \pm 1\%$  ( $n = 12$ ;  $p < 0.001$  vs. *Math1*-Cre;  $p = 0.025$  vs. *Prkce*<sup>ckO</sup>). One-way  
1069 ANOVA test. \* $p < 0.05$ . \*\*\* $p < 0.001$ . (D) Bath application of 8-pCPT (20  $\mu$ M) caused PF-EPSC  
1070 potentiation in WT mice. Left: example traces before (1) and after potentiation (2). Middle: time  
1071 course of PF facilitation. Right: percent changes of EPSC amplitude ( $179 \pm 18\%$ ;  $n = 6$ ;  $p < 0.001$ )  
1072 and PPF ( $83 \pm 3\%$ ;  $n = 6$ ;  $p < 0.001$ ) at 18-20 min vs. baseline (0-2 min). Unpaired  $t$  test. \*\*\* $p <$   
1073  $0.001$ . (E) 8-pCPT failed to induce PF-EPSC potentiation in *Prkce*<sup>ckO</sup> mice. Left: example traces  
1074 for baseline (1) and after potentiation (2). Middle: time course of PF facilitation. Right: percent  
1075 changes of EPSC amplitude ( $101 \pm 6\%$ ;  $n = 6$ ;  $p = 0.35$ ) and PPF ( $98 \pm 4\%$ ;  $n = 6$ ;  $p = 0.45$ ) at  
1076 18-20 min vs. baseline (0-2 min). Unpaired  $t$  test. (F) Co-application of 8-pCPT and  $\epsilon$ V1-2 (5  $\mu$ M)  
1077 failed to produce PF potentiation in WT mice. Left: example traces for baseline (1) and after  
1078 potentiation (2). Middle: time course of PF-EPSCs. Right: percent changes of EPSC amplitude  
1079 ( $101 \pm 4\%$ ;  $n = 6$ ;  $p = 0.78$ ) and PPF ( $101 \pm 3\%$ ;  $n = 6$ ;  $p = 0.67$ ) at 18-20 min vs. baseline (0-2

1080 min). Unpaired  $t$  test.

1081 **Figure 5.** Postsynaptic PF-PC LTP is intact upon presynaptic deletion of EPAC or PKC $\epsilon$ . (A)  
1082 Schematic showing the induction of postsynaptic LTP. (B, E, H) Example PF-EPSCs for baseline  
1083 (1) and after induction (2) in WT and *Epac*<sup>dKO</sup> PCs (B), *Math1*-Cre and *Epac1*<sup>ckO</sup>;*Epac2*<sup>ckO</sup> PCs  
1084 (E), and *Prkce*<sup>ff</sup> and *Prkce*<sup>ckO</sup> PCs (H). (C) Percentage changes of PF-EPSC amplitude. In WT,  
1085 101  $\pm$  5% for (1) and 131  $\pm$  5% for (2) ( $p < 0.001$ ). In *Epac*<sup>dKO</sup>, 100  $\pm$  5% for (1) and 106  $\pm$  6% for  
1086 (2) ( $p = 0.26$ ). Unpaired  $t$  test.  $n = 13$  for both groups. \*\*\* $p < 0.001$ . (D) Percentage changes of  
1087 PPF ratios of cells shown in (C). In WT, 100  $\pm$  2% for (1) and 100  $\pm$  3% for (2) ( $p = 0.63$ ). In  
1088 *Epac*<sup>dKO</sup>, 101  $\pm$  3% for (1) and 99  $\pm$  4% for (2) ( $p = 0.74$ ). Unpaired  $t$  test.  $n = 13$  for both groups.  
1089 (F) Percentage changes of PF-EPSC amplitudes. In *Math1*-Cre, 100  $\pm$  5% for (1) and 123  $\pm$  3%  
1090 for (2) ( $p < 0.001$ ). In *Epac1*<sup>ckO</sup>;*Epac2*<sup>ckO</sup>, 98  $\pm$  5% for (1) and 119  $\pm$  4% for (2) ( $p < 0.001$ ).  
1091 Unpaired  $t$  test.  $n = 7$  for both groups. \*\*\* $p < 0.001$ . (G) Percentage changes of PPF ratios of cells  
1092 shown in (C). In *Math1*-Cre: 100  $\pm$  2% for (1) and 96  $\pm$  3% for (2) ( $p = 0.26$ ). In  
1093 *Epac1*<sup>ckO</sup>;*Epac2*<sup>ckO</sup>: 98  $\pm$  3% for (1) and 95  $\pm$  3% for (2) ( $p = 0.28$ ). Unpaired  $t$  test.  $n = 7$  for both  
1094 groups. (I) Percentage changes of PF-EPSC amplitude. In *Prkce*<sup>ff</sup>, 99  $\pm$  4% for (1) and 121  $\pm$  4%  
1095 for (2) ( $p < 0.0001$ ). In *Prkce*<sup>ckO</sup>: 97  $\pm$  5% for (1) and 118  $\pm$  5% for (2) ( $p < 0.0001$ ). Unpaired  $t$   
1096 test.  $n = 7$  for both groups. \*\*\*\* $p < 0.0001$ . (J) Percentage changes of PPF ratios from cells shown  
1097 in (I). In *Prkce*<sup>ff</sup>, 102  $\pm$  2% for (1) and 101  $\pm$  2% for (2) ( $p = 0.73$ ). In *Prkce*<sup>ckO</sup>, 98  $\pm$  2% and 100  
1098  $\pm$  2% for (2) ( $p = 0.78$ ). Unpaired  $t$  test.  $n = 7$  for both groups.

1099 **Figure 6.** PF-LTD is unaltered by presynaptic deletion of EPAC or PKC $\epsilon$ . (A) A scheme showing  
1100 the induction of postsynaptic LTD. (B, E, H) Example PF-EPSCs for baseline (1) and after LTD  
1101 induction (2) in WT and EPAC<sup>dKO</sup> PCs (B), *Math1*-Cre and *Epac1*<sup>cKO</sup>;*Epac2*<sup>cKO</sup> PCs (E), and  
1102 *Prkce*<sup>ff</sup> and *Prkce*<sup>cKO</sup> PCs (H). (C) Percentage changes of PF-EPSC amplitude. In WT, 101  $\pm$  3%  
1103 for (1) and 59  $\pm$  5% for (2) ( $p < 0.001$ ). In EPAC<sup>dKO</sup>, 100  $\pm$  3% for (1) and 59  $\pm$  4% for (2) ( $<$   
1104 0.001). Unpaired  $t$  test.  $n = 13$  for both groups. \*\*\* $p < 0.001$ . (D) Percentage changes of PPF  
1105 ratios of cells shown in (C). In WT, 100  $\pm$  3% for (1) and 100  $\pm$  5% for (2) ( $p = 0.49$ ). In EPAC<sup>dKO</sup>,  
1106 100  $\pm$  5% for (1) and 100  $\pm$  5% for (2) ( $p = 0.26$ ). Unpaired  $t$  test.  $n = 13$  for both groups. (F)  
1107 Percentage changes of PF-EPSC amplitude. In *Math1*-Cre, 100  $\pm$  4% for (1) and 61  $\pm$  3% for (2)  
1108 ( $p < 0.0001$ ). In *Epac1*<sup>cKO</sup>;*Epac2*<sup>cKO</sup>, 101  $\pm$  3% for (1) and 65  $\pm$  4% for (2) ( $p < 0.0001$ ). Unpaired  
1109  $t$  test.  $n = 7$  for both groups. \*\*\*\* $p < 0.0001$ . (G) Percentage changes of PPF ratios of cells shown  
1110 in (F). In *Math1*-Cre, 100  $\pm$  2% for (1) and 100  $\pm$  3% for (2) ( $p = 0.40$ ). In *Epac1*<sup>cKO</sup>;*Epac2*<sup>cKO</sup>,  
1111 101  $\pm$  3% for (1) and 99  $\pm$  4% for (2) ( $p = 0.61$ ). Unpaired  $t$  test.  $n = 7$  for both groups. (I)  
1112 Percentage changes of PF-EPSC amplitude. In *Prkce*<sup>ff</sup>, 99  $\pm$  2% for (1) and 66  $\pm$  4% for (2) ( $p <$   
1113 0.0001). In *Prkce*<sup>cKO</sup>, baseline: 101  $\pm$  2% for (1) and 64  $\pm$  6% for (2) ( $p < 0.0001$ ). Unpaired  $t$  test.  
1114  $n = 7$  for both groups. \*\*\*\* $p < 0.0001$ . (J) Percentage changes of PPF ratios of cells shown in (I).  
1115 In *Prkce*<sup>ff</sup>, 101  $\pm$  2% for (1) and 101  $\pm$  2% for (2) ( $p = 0.56$ ). In *Prkce*<sup>cKO</sup>, 100  $\pm$  2% for (1) and  
1116 102  $\pm$  2% for (2) ( $p = 0.54$ ). Unpaired  $t$  test.  $n = 7$  for both groups.

1117 **Figure 7.** VOR baseline and adaptation in *Math1*-Cre, *Epac1*<sup>ckO</sup>;*Epac2*<sup>ckO</sup>, *Prkce*<sup>ff</sup> and *Prkce*<sup>ckO</sup>  
1118 mice. (A) Pictograms depicted compensatory eye movements driven by visual stimulus (OKR),  
1119 vestibular stimulus (VOR) or both (VVOR). (B) OKR gain (measure of eye movement amplitude)  
1120 and phase (measure of timing) were smaller in *Epac1*<sup>ckO</sup>;*Epac2*<sup>ckO</sup> ( $n = 16$ ) mice compared to  
1121 *Math1*-Cre ( $n = 10$ ) mice. (C) VOR was affected in *Epac1*<sup>ckO</sup>;*Epac2*<sup>ckO</sup> mice. (D) The  
1122 combination of vestibular and visual input by rotation of the mouse in the light evoked the VVOR  
1123 in *Math1*-Cre and *Epac1*<sup>ckO</sup>;*Epac2*<sup>ckO</sup> mice. (E) OKR gain and phase were smaller in *Prkce*<sup>ckO</sup> ( $n$   
1124 = 11) mice compared to *Prkce*<sup>ff</sup> ( $n = 10$ ) mice. (F) VOR was affected in *Prkce*<sup>ckO</sup> mice. (G)  
1125 VVOR gain and phase in *Prkce*<sup>ff</sup> and *Prkce*<sup>ckO</sup> mice. (H) Mismatched visual and vestibular input  
1126 was used to trigger adaptation of the eye movements in order to test motor learning ability. This  
1127 training induced a reversal of VOR phase probed by VOR recordings in the dark. (I) Both  
1128 gain-decrease learning and phase learning of *Epac1*<sup>ckO</sup>;*Epac2*<sup>ckO</sup> were impaired.  $*p < 0.05$ .  $***p$   
1129  $< 0.001$ . (J) Both gain-decrease learning and phase learning of *Prkce*<sup>ckO</sup> were impaired.  $*p < 0.05$ .  
1130  $**p < 0.01$ .  $***p < 0.001$ .

1131 **Figure 1–figure supplement 1.** Threonine phosphorylation of RIM1 by EPAC *in vitro*. (A)  
1132 Co-transfection of HA-RIM1 $\alpha$  with Flag-EPAC1 or Flag-EPAC2 in HEK cells. Arrowheads show  
1133 the co-localization of RIM1 $\alpha$  and EPACs. Scale bars: 100  $\mu$ m. (B) HA-RIM1 $\alpha$  (Ctrl) or  
1134 HA-RIM1 $\alpha$  with Flag-EPACs was transfected into HEK cells and p-Thr and p-Ser of RIM1 $\alpha$  were  
1135 measured. Arrowhead marks non-RIM1 protein. p-Thr:  $100 \pm 7$  (Ctrl),  $179 \pm 17\%$  (EPAC1;  $p =$   
1136  $0.0011$  vs. Ctrl), and  $160 \pm 13\%$  (EPAC2;  $p = 0.010$  vs. Ctrl). p-Ser:  $100 \pm 5$  (Ctrl),  $111 \pm 12\%$   
1137 (EPAC1;  $p = 0.69$  vs. Ctrl), and  $107 \pm 10\%$  (EPAC2;  $p = 0.87$  vs. Ctrl). One-way ANOVA test.  $n =$   
1138 6 for all groups. \* $p < 0.05$ . \*\* $p < 0.01$ . (C) Potential threonine phosphorylation sites by PKC in  
1139 RIM1 $\alpha$  were determined using the NetPhos 3.1 server (Technical University of Denmark; [http://](http://www.cbs.dtu.dk/services/NetPhos/)  
1140 [www.cbs.dtu.dk/services/NetPhos/](http://www.cbs.dtu.dk/services/NetPhos/)). Dashed line: threshold for phosphorylation potential.

1141 **Figure 1—figure supplement 2.** Generation of *Prkce*<sup>cKO</sup> and *Epac1*<sup>cKO</sup>;*Epac2*<sup>cKO</sup> mice and  
1142 cerebellar cytology. (A) Nissl staining in the cerebellum from WT and *Epac*<sup>dKO</sup> mice. Scale bars,  
1143 100  $\mu$ m. (B) Golgi staining showing apical PC spines. Scale bars, 2  $\mu$ m. Average numbers of  
1144 spines per 10  $\mu$ m were  $15.5 \pm 0.6$  (WT;  $n = 19$  cells) and  $14.3 \pm 0.5$  (*Epac*<sup>dKO</sup>;  $n = 19$  cells).  $p =$   
1145 0.13. Unpaired  $t$  test. (C) The construction of *Prkce*<sup>ff</sup> mice. LoxP sites were inserted before and  
1146 after exon 2 and further excised by *Math1*-Cre. (D) Native tdTomato fluorescence in the brain of  
1147 *Math1*-Cre;Ai9 mouse. Scale bars: 1 mm. (E) Granule cell contents of *Prkce*<sup>ff</sup> and *Prkce*<sup>cKO</sup> mice  
1148 were harvested using glass micropipettes and subjected to RT-PCR. *Prkce* (165 bp) was absent in  
1149 *Prkce*<sup>cKO</sup> granule cells. \*\*\*\* $p < 0.0001$ . (F) PKC $\epsilon$  expression in the cerebellum from *Prkce*<sup>ff</sup> and  
1150 *Prkce*<sup>cKO</sup> mice. Percentage changes of PKC $\epsilon$ :  $100 \pm 2\%$  (*Prkce*<sup>ff</sup>;  $n = 6$ ) and  $34 \pm 4\%$  (*Prkce*<sup>cKO</sup>;  $n$   
1151 = 6). Unpaired  $t$  test. \*\*\*\* $p < 0.001$ . (G) Nissl staining in the cerebellum. Scale bars, 100  $\mu$ m.  
1152 GCL thickness:  $111.0 \pm 4.9 \mu$ m (*Prkce*<sup>ff</sup>) and  $111.6 \pm 5.4 \mu$ m (*Prkce*<sup>cKO</sup>),  $p = 0.93$ , unpaired  $t$  test.  
1153 ML thickness:  $151.7 \pm 5.3 \mu$ m (*Prkce*<sup>ff</sup>) and  $148.4 \pm 5.3 \mu$ m (*Prkce*<sup>cKO</sup>),  $p = 0.64$ , unpaired  $t$  test.  $n$   
1154 = 7 for all groups. (H) Golgi staining showing apical PC spines in *Prkce*<sup>ff</sup> and *Prkce*<sup>cKO</sup> mice.  
1155 Scale bars, 2  $\mu$ m. Average numbers of spines per 10  $\mu$ m:  $15.8 \pm 0.6$  (*Prkce*<sup>ff</sup>;  $n = 29$  cells) and  
1156  $15.7 \pm 0.6$  (*Prkce*<sup>cKO</sup>;  $n = 28$  cells),  $p = 0.88$ , unpaired  $t$  test. (I) The construction of *Epac2*<sup>ff</sup> mice.  
1157 LoxP sites were inserted between exons 6 and 9 and further excised by *Math1*-Cre. (J) Granule  
1158 cell contents of *Epac2*<sup>ff</sup> and *Epac2*<sup>cKO</sup> mice were harvested and subjected to RT-PCR. *Epac2* (180  
1159 bp) was absent in *Epac2*<sup>cKO</sup> granule cells. \*\*\*\* $p < 0.001$ . (K) The construction of *Epac1*<sup>ff</sup> mice.  
1160 LoxP sites were inserted between exons 3 and 18 and further excised by *Math1*-Cre. (L) Granule  
1161 cell contents of *Epac1*<sup>ff</sup> and *Epac1*<sup>cKO</sup> mice were harvested and subjected to RT-PCR. *Epac1* (218  
1162 bp) was absent in *Epac1*<sup>cKO</sup> granule cells. \*\*\*\* $p < 0.001$ .

1163



1164 **Figure 1—figure supplement 3.** 8-pCPT-induced RIM1 phosphorylation is blocked by PKC $\epsilon$   
1165 inhibitor. (A) Flag-RIM1 $\alpha$  (Ctrl) or Flag-RIM1 $\alpha$  with HA-EPACs was transfected into HEK cells,  
1166 and the phosphorylation and expression of PKC $\epsilon$  and PKC $\alpha$  were normalized to  $\beta$ -actin. For  
1167 percentage change, pPKC $\epsilon$  was  $100 \pm 5\%$  (Ctrl),  $179 \pm 13\%$  (EPAC1;  $p = 0.0003$  vs. Ctrl), and  
1168  $160 \pm 12\%$  (EPAC2;  $p = 0.003$  vs. Ctrl); PKC $\epsilon$  was  $100 \pm 6\%$  (Ctrl),  $99 \pm 8\%$  (EPAC1;  $p = 0.96$  vs.  
1169 Ctrl), and  $101 \pm 8\%$  (EPAC2;  $p = 0.92$  vs. Ctrl); PKC $\alpha$ -pS was  $100 \pm 7\%$  (Ctrl),  $101 \pm 10\%$   
1170 (EPAC1;  $p = 0.94$  vs. Ctrl), and  $96 \pm 8\%$  (EPAC2;  $p = 0.67$  vs. Ctrl); and PKC $\alpha$ -pT was  $100 \pm 6\%$   
1171 (Ctrl),  $97 \pm 10\%$  (EPAC1;  $p = 0.81$  vs. Ctrl), and  $101 \pm 8\%$  (EPAC2;  $p = 0.90$  vs. Ctrl). One-way  
1172 ANOVA test.  $n = 6$  for all groups.  $**p < 0.01$ .  $***p < 0.001$ . (B) Precleared synaptosomes from  
1173 WT mice were immunoprecipitated with anti-RIM1 antibody and probed with antibodies to PKC $\epsilon$   
1174 and RIM1.  $n = 4$ . (C) HA-RIM1 $\alpha$  (Ctrl) or HA-RIM1 $\alpha$  with His-PKC $\epsilon$  was transfected into HEK  
1175 cells and p-Thr and p-Ser of RIM1 $\alpha$  were analyzed. p-Thr and p-Ser were normalized to HA and  
1176 percentage changes relative to Ctrl are plotted. p-Thr was  $100 \pm 8\%$  (Ctrl) and  $179 \pm 18\%$  (PKC $\epsilon$ ;  
1177  $p = 0.0021$ ). p-Ser was  $100 \pm 11\%$  (Ctrl) and  $118 \pm 13\%$  (PKC $\epsilon$ ;  $p = 0.26$ ).  $n = 5$  for all groups.  
1178 Unpaired  $t$  test.  $**p < 0.01$ . (D) Synaptosomes (WT) were treated with control buffer, 8-pCPT (20  
1179  $\mu$ M, 30 min), 8-pCPT+ $\epsilon$ V1-2 (5  $\mu$ M, 30min) and 8-pCPT+Gö (10  $\mu$ M, 30 min). p-Thr was  
1180 normalized to RIM1 and percentage changes relative to Ctrl are plotted. Ctrl:  $100 \pm 8\%$ . 8-pCPT:  
1181  $280 \pm 35\%$  ( $p = 0.0016$  vs. Ctrl). 8-pCPT+ $\epsilon$ V1-2:  $147 \pm 19\%$  ( $p = 0.58$  vs. Ctrl;  $p = 0.015$  vs.  
1182 8-pCPT). 8-pCPT+Gö:  $276 \pm 31$  ( $p = 0.0019$  vs. Ctrl;  $p = 0.99$  vs. 8-pCPT;  $p = 0.017$  vs.  
1183 8-pCPT+ $\epsilon$ V1-2). One-way ANOVA test.  $n = 4$  for all groups.  $*p < 0.05$ .  $**p < 0.01$ . (E)  
1184 Synaptosomes (WT) were treated with control buffer, PMA (1  $\mu$ M, 30 min), PMA+ $\epsilon$ V1-2 (5  $\mu$ M,  
1185 30min) and PMA+Gö (10  $\mu$ M, 30 min). RIM1 p-Thr was normalized to RIM1, and percentage


1186 changes relative to Ctrl are plotted. Ctrl:  $100 \pm 8\%$ . PMA:  $208 \pm 19\%$  ( $p = 0.0041$  vs. Ctrl).  
1187 PMA+ $\epsilon$ V1-2:  $134 \pm 13\%$  ( $p = 0.55$  vs. Ctrl;  $p = 0.043$  vs. PMA). PMA+Gö:  $214 \pm 24\%$  ( $p =$   
1188  $0.0029$  vs. Ctrl;  $p = 0.99$  vs. PMA;  $p = 0.030$  vs. PMA+ $\epsilon$ V1-2). One-way ANOVA test.  $n = 4$  for  
1189 all groups.  $*p < 0.05$ .  $**p < 0.01$ .

1190 **Figure 3—figure supplement 1.** Presynaptic PF-PC LTP is blocked by forskolin incubation, EPAC  
1191 ablation, or  $\epsilon$ V1-2 application. (A) Example PF-EPSCs for baseline (1) and after LTP induction (2)  
1192 in a WT PC perfused with forskolin (20  $\mu$ M). (B) Percentage changes of PF-EPSC amplitude with  
1193 forskolin treatment in WT mice:  $99 \pm 3\%$  (1) and  $101 \pm 5\%$  (2);  $n = 11$ ;  $p = 0.63$ . PPF ratios from  
1194 cells shown in the left panel:  $100 \pm 5\%$  (1) and  $102 \pm 4\%$  (2);  $n = 11$ ;  $p = 0.72$ . Unpaired  $t$  test. (C)  
1195 Example PF-EPSCs for baseline and after LTP induction in an *Epac*<sup>dkO</sup> PC. (D) Percentage  
1196 changes of PF-EPSC amplitude in *Epac*<sup>dkO</sup> mice:  $100 \pm 3\%$  (1) and  $104 \pm 5\%$  (2);  $n = 11$ ;  $p = 0.66$ .  
1197 PPF ratios from cells shown in the left panel:  $99 \pm 5\%$  (1) and  $104 \pm 5\%$  (2);  $n = 11$ ;  $p = 0.58$ .  
1198 Unpaired  $t$  test. (E) Example PF-EPSCs for baseline and after LTP induction in a WT PC perfused  
1199 with  $\epsilon$ V1-2 (5  $\mu$ M). (F) Percentage changes of PF-EPSC amplitude in WT mice:  $100 \pm 3\%$  (1) and  
1200  $101 \pm 4\%$  (2);  $n = 9$ ;  $p = 0.59$ . PPF ratios from cells shown in the left panel:  $101 \pm 4\%$  (1) and  $102$   
1201  $\pm 5\%$  (2);  $n = 9$ ;  $p = 0.22$ . Unpaired  $t$  test.


1202 **Figure 7–figure supplement 1.** Impaired VOR learning in *Epac*<sup>dKO</sup> mice. (A) Gain and phase  
1203 values of WT ( $n = 10$ ) and *Epac*<sup>dKO</sup> ( $n = 10$ ) mice during OKR evoked by visual stimulation.  $**p$   
1204  $< 0.01$ . (B) Gain and phase values of WT and *Epac*<sup>dKO</sup> mice evoked by vestibular stimulation in  
1205 the dark.  $*p < 0.05$ .  $**p < 0.01$ . (C) Gain and phase values of WT and *Epac*<sup>dKO</sup> mice during  
1206 VVOR in the light. With visual input, the VOR deficits in *Epac*<sup>dKO</sup> were no longer present. (D)  
1207 VOR recordings in the dark revealed a reversal of VOR phase in WT and *Epac*<sup>dKO</sup> mice.  $*p < 0.05$ .  
1208  $**p < 0.01$ .  $***p < 0.001$ .

1209 **Figure 7–figure supplement 2.** Proposed schematic model for the function of EPAC-PKC $\epsilon$   
1210 module in presynaptic LTP and motor learning. In this model, EPAC activation by forskolin or  
1211 presynaptic tetanus stimulation promotes PKC $\epsilon$  activation and phosphorylation threonine of RIM1,  
1212 which further facilitates the assembly of Rab3A-RIM1-Munc13-1 tripartite complex and the  
1213 docking of vesicles at active zones. All these events are required for the induction of presynaptic  
1214 LTP. Importantly, presynaptic LTP is essential to VOR phase adaptation learning.










































**A****B****C****D****E****F****G****H****I****J**




A













B



C












A




B




C












D



E













**A**



OKR

**B**



VOR

**C**

VVOR

**D**


VOR phase reversal




bioRxiv preprint doi: <https://doi.org/10.1101/2022.06.15.496388>; this version posted June 17, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.



# Parallel fiber



bioRxiv preprint doi: <https://doi.org/10.1101/2022.06.15.496308>; this version posted June 17, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.



## Presynaptic LTP

## Motor learning

